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CHAPTER I
INTRODUCTION AND MOTIVATION
Cancer is a pandemic as widespread as any major disease, affecting millions around the
world, and though some research in cancer therapy is aimed at preventative measures and
strengthening the immune system to recognize and combat it, the vast majority of research
is an exercise in cell killing. Good therapeutic techniques are both selective and efficient,
sparing healthy tissue and using as little foreign intervention in the body as possible; most
fall in two primary modalities: chemo- and radiation therapy.
Chemotherapy, at its heart, is the ingestion of poison: toxic pharmaceuticals that scien-
tists attempt to design with tumors cells as their target. Discoveries in biology, chemistry,
and pharmacology have led to hundreds of new drugs that have advanced this modality to,
in many cases, an oncologist’s first choice in cancer treatment. Fundamentally though, the
development of these techniques is predicated on finding ways in which cancer cells are
different from normal cells, whether it be an over- or under-expression of certain antibod-
ies or enzymes. The fact remains that there are millions of such minute differences among
various types of normal cells, never-mind between them and cancer cells. Even more chal-
lenging is the fact that within a certain class of cancer, breast cancer for example, there is
huge variation of biological composition and so dedicated treatments for one variant could
be completely useless for others. Furthermore, any single mutation of a normal cell can
form a cancerous one that will proliferate and spread, so identifying these small number of
mutations in our enormous genome is a daunting task.
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Radiation therapy depends much less on cancer biology and human physiology and
so its effects can be more easily predicted and its administration more readily controlled.
Once the tumor is identified as cancer, usually by the physician after analysis of a biopsy,
and located with millimeter accuracy by computed tomography (CT) (or alternative diag-
nostic scan), the medical physicist can use an arsenal of treatment planning software and
particle accelerators to deliver a lethal dose of radiation to the target volume with strict
limitations on the dose to peripheral, healthy tissue. There are various techniques in radia-
tion therapy, all of which aim to control the homogeneity of dose within the tumor as well
as the limitation of dose elsewhere. Much of the methodology revolves around the idea
that dose is additive and so at the intersection of two beams the dose is amplified while
along the track of each individual beam, dose is limited. Use of enough beams at distinct
angles can provide sufficient cumulative dose to the tumor volume, but even though the
dose along each track is minimal compared to the tumor’s, many healthy organs will have
been exposed to some radiation along these paths. Intensity modulated and image guided
radiotherapy (IMRT and IGRT) in their various forms are the current state-of-the-art solu-
tion to this dilemma. Current accelerators house pneumatic collimators, robotic arms, and
on board monitoring systems to meticulously control the shape, intensity, and direction of
the radiation beam to fit the pre-planned dose distribution criteria. Though huge advances
in these technologies have led to much clinical success, they still share an inherent flaw.
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Figure 1.1: Absorption coefficients and corresponding penetration depths of photons and
electrons in water across the spectrum. Photon data is linear interpolated between data
1.24 nm - 124 fm (Seltzer, 1993) and 10 - 1010 nm(Segelstein, 1981; Querry et al., 1991).
For photons, actual data are mass-energy absorption coefficients and penetration depth is
defined as the 1/e value. For electrons, data are penetration depths as calculated in the con-
stant slow down approximation (CSDA) (Berger et al., 2008; Meesungnoen et al., 2002).
1.1 The Hazards of Targeting Water
The human cell is comprised primarily of water. The majority of radiotherapy tech-
niques use megavoltage radiation, whether photons or electrons, for the penetration power.
Figure 1.1 shows the absorption and penetration of photons and electrons in water through-
out the spectrum. Except for photons in the visible spectrum, water is most transparent
in the megavoltage range for both types of radiation. While wielding the ability to access
tumors at significant depth in the body, fundamentally, these techniques surrender to the
weakest possible absorption mechanism. Consequently, extremely high flux is necessary
in accelerators to deliver a sufficient number of photons to achieve prescribed doses.
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With absorption in mind, people have also experimented in other energy regions to
target water. Lasers focused at many of the small peaks in infrared region of Figure 1.1
have been explored in attempts to sufficiently heat up the water in tumor cells to toxic
levels. Well studied vibrational resonances in water in the microwave spectrum have also
led to thermal toxicity in tumors. These techniques are successful in vitro, yet share the
same inherent flaw: tumor cells are comprised of as much water as are healthy ones and so
to radiation, normal cells and tumor cells look identical. There is no contrast in these
types of therapy and so the specificity of the treatment falls entirely on the therapist’s
ability to focus the beam, leading to similar problems as above. The inverse relationship
of absorption to penetration is the limitation of external beam therapy: if the beam can
penetrate deep enough to reach non-superficial tumors, then the absorption is so low that
you need a large number of photons to achieve toxic dose; if the absorption is high, then
not only cant you reach deep tumors, but healthy cells along the beam path are at similar
risk as the tumor.
1.2 Local LET
In principle, a better technique would be one that can somehow penetrate deep into the
body and whose radiation is specifically absorbed in tumor cells only. More than simply
being absorbed, the radiation needs to be lethal where it is absorbed. Relative biological
effectiveness (RBE), though arbitrarily defined, is a way to compare the lethality of the
same absorbed dose of two different radiation sources. In studies to find the optimum
cell-killing radiation, researchers have tracked the dependence of RBE on a wide range of
4
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Figure 1.2: RBE vs. LET. Data re-digitized from Barendsen (1968).
variables. Perhaps the most general and informative peak is found in the dependence of
RBE on linear energy transfer (LET)–the energy transferred per unit length of the track of
radiation–a quantity that takes into account both the type and energy of radiation; Figure
1.2 shows this distinct peak.
LET is clearly linked with our analysis of absorption/penetration, the difference being
the consideration of whether the energy lost from the particle is absorbed locally, or if it
spawns other particles that transport the dose at a distance from the site of initial interaction.
For electrons above 1 eV, the lower the energy, the higher the LET, as the lower energy par-
ticles deposit their dose in shorter ranges. This analysis holds only in the ionizing radiation
energy range. Electrons, being charged particles, have the power to ionize through their
entire energy spectrum, while photon ionization potential drops significant below 13.6 eV,
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the binding energy of the lowest energy orbital electron in the hydrogen atom (more on the
mechanisms of ionization to follow). External beams of radiation with high enough LET
to be biologically destructive will not penetrate to sufficient depths without large amounts
of collateral damage, but if such high-LET radiation can be made to originate within the
tumor, and deliver all of its dose locally, then healthy tissue can be spared while tumor
cells destroyed. While protons, α-particles, and heavier ions have increasingly higher LET
because of their greater mass and charge, they have their own “red flags” ranging from
higher costs to radiation safety. Electrons, however, especially low energy electrons, have
LET values that approach those of heavy charged particles, and thus have higher RBEs than
photons or mederate energy electrons. If a low energy electron emitter can be introduced
locally to tumor cells, cell killing can be more readily controlled and more effective.
1.3 Radiobiology of Cell Killing
But what does localmean? In order to select the target of our radiation we must identify
an efficient mechanism by which radiation kills cells. Perhaps the most efficient way to kill
a cell is by double stranded breaks (dSB) in the nuclear DNA; that is, two strand breaks
within ~10 bases of each other. Though there are more than 6.3× 109 base pairs in the
genome of one human cell, only one non-repairable dSB in that cell can lead to its death
(Dahm-Daphi et al., 1994). This is a hugely efficient mechanism and though there are other
techniques in cell killing, from thermal to pharmacological, in comparison they are akin to
using the energy it takes to bash a computer to pieces with a hammer, when a simple virus
changing its code can render it useless.
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With DNA as the critical target, radiation can cause the breaks in two ways. It is
possible for radiation to be absorbed by the atoms of the DNA macromolecules directly, in
which case the atoms are ionized or excited, and can initiate the chain of events that leads
to a break. With high-LET radiation, this “direct” process dominates because the density of
ionization from this radiation is high enough so that the spacing between ionizing events is
shorter than distance scale of the macromolecules. In fact, we have gotten a glimpse of this
idea through the peak in RBE, which occurs at 100 keV/µm. In more convenient units, this
translates to 100 eV/nm, which given the 2 nm diameter of the DNA double helix, means
that about 200 eV is deposited as this high-LET radiation passes through the DNA. This
gives a ballpark value for the amount of energy it takes to most efficiently break the bonds
in DNA. This value is believable since it only takes about ~5 eV to break these bonds (UV
sunlight at this energy will do enough biological damage to burn the skin) and so it makes
sense that at an energy just above this, the process is most efficient.
The incident radiation, however, is not the only potential ionizer; in fact, it may not
even be the most effective. If instead the radiation interacts with water, the most prevalent
molecule in the cellular environment, several highly reactive products can be created; the
dominant final product species are electrons and hydroxyl radicals. For example, radiation
incident on water can produce an aqueous electron and an ionized water molecule. The
electron often gets trapped by the polarity of two water molecules; its lifetime in this tran-
sient state is about 1 ms, which is relatively long compared to other species of products.
The ionized water molecule is charged and has an unpaired electron making it both an ion
and a free radical, so very unstable. This ion radical breaks up into a hydrogen ion and an
hydroxyl radical, which is highly reactive having a lifetime of about 1 ns and a range of
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about 1-2 nm in cells. This “indirect” process is thought to account for about two-thirds
of all mammalian DNA damage caused by x-rays (Hall and Giaccia, 2006). What this
suggests is that if a water molecule is ionized within a cylinder of about 4 nm (twice the
diameter of a DNA double helix) the hydroxyl radical can diffuse to the DNA and oxidize
it by extracting a hydrogen atom and leaving a radical site on the DNA. Such damage can
lead to bases being altered or the sugar phosphate backbone being broken.
Still, targeting water, or even DNA, with external photons is not ideal; we have already
examined the absorption issues of water and DNA’s absorption peak also occurs outside
the therapeutic x-ray region at 260 nm (this fact lies at the heart of spectrophotometry,
which will be used in this study to verify the density of DNA in our cell line). We have
seen, however, that electrons are more potent ionizers, especially low-energy ones which
have short track lengths along which they deposit all of their dose. A goal for an effective
cell killing mechanism would then be to produce low energy electrons whose origin (and
therefore site of maximal energy deposition) is within twice the DNA helix diameter. These
electrons would have the potential to ionize the DNA molecules directly, as well as the
surrounding water molecules, whose resultant products can produce similar lethal lesions.
1.4 Effectively Stimulating Electrons
There are several ways in which photons can induce the emission of electrons, the
most relevant to this study being the photoelectric effect. When an incident photon has
energy above the binding energy of an orbital electron, the electron absorbs the photon
entirely and is emitted from the atom with the energy difference between the initial photon
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and the binding energy imparted as kinetic energy. This is a moderately efficient process
in that for one incident photon, one electron is emitted. The resultant atom is left with
an electron vacancy that will be filled by electrons from higher energy orbitals, and the
process of creating and filling electron “holes” will continue until the highest energy orbital
is eventually filled from the vacuum. With each electron transition, energy is conserved by
either of two processes. Fluorescence is the emission of characteristic x-rays with energy
equal to the difference in binding energy of the two states. The Auger process fills the
same gaps by the emission of electrons; upon ejection, the kinetic energy of the Auger
electron (which comes from a higher shell in the same atom) corresponds to the difference
between the energy of the initial electronic transition and the binding energy for the electron
shell from which the Auger electron was ejected. These Auger electrons then necessarily
have lower energy than the fluorescent x-rays, because most of the energy from the initial
transition is used to free the bound electron. The low energy and short range of these
electrons are the sources of their potency in cell killing (see Section 4.1).
Fluorescence yields are highest for core shell (K-) electron holes, but for L- and M-
shells, the Auger process strongly dominates as seen in Figure 1.3. What this means is that
for atoms with Z ≥ 19 (atoms with an M-shell), if an incident photon causes an inner-shell
ionization (ISI), the subsequent emission spectrum will consist of the photoelectron, a low-
energy fluorescent x-ray, and at least two low-energy Auger electrons. Also, for Z ≥ 36
and Z ≥ 54 atoms have an additional N- and O-shell, respectively, and though not shown
in the plot, the Auger yields for these shells are nearly unity. Furthermore, if the incident
photon can be tuned as closely as possible above the K-edge of the target atom, the energy
of the photoelectron can be reduced. Now we can see the potential of this being a efficient
9
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Figure 1.3: K-, L-, and M-shell Auger yields for 1≤ Z ≤ 100. *Data are actually (1−ωi)
where ωi are fluorescence yields of the ith shell taken from Hubbell et al. (1994). L- and
M-shell values are averages over all subshells. Coster-Kronig electrons are included, but
not distinguished here.
mechanism for low energy electron yield from external radiation: one incident photon can
spawn 3+ low energy, high-LET electrons as well as another low energy photon, which can
spawn similar chains. Note: Coster-Kronig transitions, (the special case of Auger process
in which the vacancy is filled by an electron from a higher subshell of the same shell)
which are fairly prevalent in L- and higher shells, increase the number of electrons emitted
during the restabilization cascade while decreasing each’s energy. This process increases
the number and ionizing power of the emitted electron spectrum.
Even though Auger yields are highest for lowest-Z materials, we have discussed how
water is not our target; we need something to optimize contrast and the most effective tar-
get would be that which absorbs greatest in contrast to water. Figure 1.4 is a plot of the
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absorption coefficient just above an elements K-edge sorted by atomic number; also plotted
is its absorption relative to water. The curve decreases with heavier elements (as Comp-
ton scattering takes over as the dominant photon interaction at higher energies) despite the
~Z4/E3 dependence since the K-edge spacing is not constant; this variability can be seen
in the top axis in the figure. It should be clear that based solely on absorption, the most
effective target materials would live in the range 44￿ Z ￿ 54. The choice of target material
also determines the necessary energy range of the activating radiation source; absorption
has a fairly narrow peak just above the atom’s K-edge, and so in order to take full advan-
tage, the radiation source should be centered 10-15 keV above the K-edge with an energy
distribution no more than 20-30 keV wide.
Thus far we have outlined two important criteria for selecting the ideal material to
be used as a target in radiation-based cell killing, while simultaneously identifying the
optimum energy range of the activating radiation source. Fortunately, it happens that the
elements whose absorption characteristics distinguish themselves most substantially from
water also lie in the range of atoms with available N-shell electrons and considerably high
Auger yields. So not only will these targets stand out in the cellular environment, but once
activated will mount a potent attack on the cell. Perhaps the most important issue, though,
is how to get the target material into the cellular environment. This uptake can not be
arbitrary, but specifically into tumor cells only, as we have argued that effective cell killing
will occur wherever both the target material and activating radiation are present.
11
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Figure 1.4: Absorption Cross Section at K-edge vs. Atomic Number, Z. Right axis is ratio
of absorption coefficient just above element’s K-edge to that of water at same energy.
1.5 Tumor Specificity
Perhaps the easiest and least variable method to differentiate tumors from normal cells
is the length of the cell cycle. Tumor cells, for the most part, proliferate much more rapidly
than do healthy cells (with some exceptions: bone marrow, intestinal endothelium). If the
target material can be introduced through a process that only occurs during cell prolifera-
tion, it can lead to high tumor specificity.
During S-phase of the cell’s mitotic cycle, DNA replicates itself into two identical
copies. Basically, the double helix splits into individual strands, and since pairing of bases
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is unique (adenine always pairs with thymidine (A = T ) through two hydrogen bonds and
cytosine always pairs with guanine (C ≡ G) through three bonds) each strand of the DNA
carries all of the genetic information. There are several competing processes by which the
cell pairs the corresponding base to the single “unzipped” DNA strand; the dominant two
are through an enzyme called DNA polymerase and through de novo synthesis. DNA poly-
merase searches the existing pools of DNA bases and governs the transport of an available,
suitable base to the exposed site of the DNA strand. Alternatively, a synthase enzyme can
catalyze de novo synthesis of the necessary base, which is then used similarly to complete
the pairing (more on this competition later). If a target material can be attached to or dis-
guised as one of the DNA bases and enough of it introduced into the intracellular pools,
then it would be plausible to selectively incorporate the target material into nuclear DNA
of only tumor cells.
1.6 The Solution
This tumor-avid uptake, along with an enhanced absorption contrast to water and a ro-
bust electron emission spectrum, constitutes the criteria for optimum radiosensitizer; iodo-
deoxyuridine (IUdR) meets all three standards. Iodine, as well as the rest of the halogens,
just so happen to “look” like a methyl group in a chemical sense. Like the methyl group,
halogens are one electron short of stability and have van der Waal’s radii of approximately
200 pm (Prusoff et al., 1979). As such, the halogens can be substituted for the methyl group
in the DNA base thymidine to make up what are called halogenated pyrimidine analogues.
The chemical structure is so similar that these analogues are nearly indistinguishable to the
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cell and will populate the thymidine pools from which DNA polymerase searches when
there is an unpaired adenine during DNA replication; this process is called the thymidine
salvage pathway. Of the halogens, iodine is not only closest in size to the methyl group
and so should be maximally incorporated, but is also the only one that lives in the optimum
target range discussed above (Z=53, K-edge @ 33.2 keV).
Besides the microbiological highlights, there are several other factors that classify the
use of IUdR as advantageous. If successfully substituted in the DNA, IUdR is biologically
stable. In the human body, iodine that is not taken up in the DNA is directed to the thyroid
gland, and then eventually excreted with biological half-lives reported from to be on the
order of minutes to hours (O’Farrel and Dunuaway, 1969; Semnani et al., 2005). Adminis-
tration of IUdR days before radiation treatment will ensure that non-substituted iodine will
not linger. This isolation dilemma is one of the most important hindering the use of ra-
dioactive iodine in a similar fashion. Studies have shown extreme efficacy of cell killing in
tumors through 125IUdR therapy(Faraggi et al., 1994; Commerford et al., 1980; van Dieren
et al., 1996), but others have also tracked the dose to the liver as the non-substituted iodine
leaves the body (Kinsella et al., 1994). In fact, radioactive IUdR is used as a proliferation
tracer of tumors in the liver. Since iodine builds up in the liver, the dose of radiation coming
from the 125IUdR is used to monitor the rate of cell proliferation. Using externally initiated
radiation with stable iodine allows the therapy to be isolated where only the substitution in
the region of irradiation is toxic.
It is clear from Figure 1.4 that if it is feasible to operate at lower photon energies, ra-
diosensitizing materials like iodine would be more efficiently absorbed in cells than higher-
Z materials, regardless of sensitizing mechanism. This idea has been discarded in the past
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because of the inadequacies of external beams of such low energy. Almost all the dose
from low energy photons is deposited at the interaction site and so external, low energy
beams fail to treat non-superficial tumors without doing much collateral damage along the
beam path. Also, chemotherapeutic and radiosensitizing drugs containing platinum (Z=78,
K-edge @78.4 keV), for example, have shown some promise in the clinic. Still, these have
be combined with megavoltage x-rays and so lack an efficient absorption mechanism. If,
however, the more efficiently absorbed, low energy x-rays were administered from within,
as in brachytherapy, this synergy of enhanced absorption contrast and tumor specificity can
be taken advantage of.
1.7 Brachytherapy and its Past Inadequacies in Combination Therapy
Brachytherapy involves implanting radioactive material in the body with close proxim-
ity to the tumor. Medical physicists have written and implemented robust treatment plan-
ning software to account for heterogeneous tissue, attenuation, and anisotropic dose deliv-
ery, so treatment of lesions ranging from minuscule metastases to golf-ball-sized tumors
have been well developed. Manual localization of the radiation source ensures consistency
of treatment distance, predictability of dose distribution, and perhaps most importantly,
the tumor can be treated with a high dose of radiation, while reducing the probability of
damage to healthy tissue. For instance, it is potentially harmful to irradiate the lung, but
using external beam therapy to target the pancreas, it is difficult to achieve significant dose
with one beam without substantial damage along the beam path and even more difficult to
use distinct beams without one of them bypassing a lung. For this reason, along with the
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Table 1.1: Common Brachytherapy Materials
Radionuclide Half-life Photon Energy (MeV) Exposure rate constant Γ( R ˙cm2mCi·h˙r)
226Ra 1600 yr 0.047-2.45 (0.83 avg) 8.25
222Rn 3.83 days 0.047-2.45 (0.83 avg) 10.15
60Co 5.26 yr 1.17, 1.33 13.07
137Cs 30.0 yr 0.662 3.26
192Ir 73.8 days 0.136-1.06 (0.38 avg) 4.69
198Au 2.7 days 0.412 2.38
125I 59.4 days .028 avg 1.46
103Pd 17.0 days .021 avg 1.48
convenience of outpatient procedures, brachytherapy patients often have lower risks of the
adverse side effect associated with radiation therapy.
Common seed materials for brachytherapy are listed in Table 1.1, along with their half-
lives and average energy. Notice how the common radioisotopes fall into two basic cate-
gories: low and high energy. Herein lies the clue to their ineffectiveness in combination
therapy. The higher energy seeds have a larger penetration depth and can therefore deliver
dose to larger tumors. The thing to note, however, is that above about 80 keV, more that
92% of photon interactions in water are Compton scattering processes where much less
energy is transferred, and so full absorption is not localized to the site of the initial inter-
action. Photoelectric absorption accounts for less than 3% of interactions (but 21% of the
energy transferred) at 80 keV and this percentage falls dramatically over 200 keV to 0.1%
of the interactions (and 1% of the energy transferred) (Johns and Cunningham, 1983). It is
clear that higher energy photons, although having their benefits, do not take advantage of
any efficient absorption mechanism and therefore are not ideal for targeting radiosensitiz-
ers. The low energy seeds take advantage of the relatively high absorption and are effective
as a stand alone therapy for small tumors Sloboda (2003); Sharkey et al. (2002). Notice,
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however, that both 125I and 103Pd emit the majority of their radiation below the 33 keV
K-edge of iodine and so again do not take full advantage of this photo-absorptive contrast.
This explains their inefficiency in combination therapy despite their relative effectiveness
as stand alone radiation sources. It should be clear that a low energy photon source, just
above the K-edge of iodine would take advantage of the iodine photo-absorption, the ab-
sorptivity contrast relative to water, and the fact that 80% of the total energy transferred to
water at this energy is done through photoelectric processes.
Interest in low energy brachytherapy has increased over the last decade and people have
began to develop different ways to make these low-energy x-rays. An alternate technique
that has been getting more attention is implantable x-ray tubes. The so-called “electronic
brachytherapy” consists of a miniature x-ray tube the size of a resistor connected to a
portable controller that can adjust the operating voltage up to 50 kVp and therefore change
the dosimetric properties of the therapy. Much work has been put into doing a dosimetric
characterization of these mini tubes, but their use remains experimental (Beatty et al., 1996;
Gutman et al., 2004; Liu et al., 2008). Alternatively, synchrotrons and Compton back-
scattering accelerators are able to provide clean x-ray beams at this energy with sufficient
flux to be useful. Though much research has been done using these tunable beamlines to
find the optimum activation energy for IUdR (Corde et al., 2004), these existing sources of
monochromatic x-rays at this energy are prohibitively expensive and geographically sparse,
and so support for this theoretically efficient combination has been abandoned for practical
reasons. Search for a useful activation source led us to nuclear physics.
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1.8 Narrowing the Search
The prime candidate for a brachytherapy material, given IUdR as the target, is a narrow
band x-ray source with photon energy centered at 50 keV, above the 33 keV K-edge of
iodine at the peak of the absorption contrast relative to water (see Figure 4.1). With that
in mind a search of the entire periodic table can be narrowed substantially. This photon
energy lies in the x-ray region, and more specifically the K-x-rays (even the heaviest ele-
ments feasibly produced have L-edges below iodine’s K-edge). These x-rays come from
atomic transitions, but can be produced after nuclear decay. The relevant process is elec-
tron capture (EC) where an inner-shell electron is absorbed by the nucleus. The electron
combines with a proton to form a neutron and an energetic neutrino. Since the number
of protons decreases by one while the number of neutrons increases by one, the resultant
nuclide is different from the original, but the atomic mass number remains unchanged. The
subsequent atom is now in an excited state with an inner-shell electron vacancy, and will
restabilize itself through fluorescence or the Auger process as discussed earlier. Recall that
fluorescence dominates at higher-Z (elements whose K-edge is high enough to generate
characteristic K-x-rays in our target energy range) and so as the electron hole is filled, nar-
row band x-rays will follow. Other possible outcomes of EC decay are the population of
excited nuclear states of the resultant nuclide or even ground states of unstable nuclides
that will undergo subsequent decay. The criteria for our search is then limited to nuclides
1) who undergo EC only (with no probability of α−or β− decay since these lead to other
radiation absorption mechanisms that could be detrimental to healthy cells with no IUdR
incorporation), 2) that decay mainly into the nuclear ground state of a stable daughter nu-
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clide (eliminating high-energy γ−rays from excited nuclear state transitions), 3) whose
characteristic K-x-rays fall between 40-60 keV, and 4) that decay with a relatively short
half-life. Brachytherapy treatment plans often call for low dose fractions and so to limit
the handling dose to personnel and require much less strict removal times, it is beneficial
to have the source decay completely while implanted. Also, long-lived radioactive mate-
rials have a list of safety concerns unto themselves. Despite the vast number of available
nuclides in this energy range (NNDC, 2009), only one nuclide fits all the criteria. 161Ho
is a pure electron capture agent that decays mainly into the nuclear ground state of 161Dy;
excited nuclear states of dysprosium are very rarely populated. With a 2.54 hour half-life,
the decay produces atomically excited states of dysprosium with an inner-shell electron
vacancy. As the atom restabilizes, the electrons reorganize to fill this hole, and the dyspro-
sium atom emits its characteristic x-rays (Kα,β@ 45 and 52 keV, respectively). The low
energy L- and M- x-rays are easily filtered out, and so the spectrum consists principally of
K x-rays, free of long-lived or beta-decaying isotopes.
The goals for this project were twofold: first, to create, characterize, and measure the
amount of holmium we were able to produce; and second, to carry out in vitro studies to de-
termine if this combination of radiosensitizer and x-ray source was, in fact, more effective
in cell killing than other treatment modalities. Before the second goal was accomplished
though, there was a need to develop the analytical machinery to define what “effective”
meant, and which mechanisms of dose enhancement and sensitization led to cell killing.
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CHAPTER II
CREATING AND MEASURING RADIOACTIVE HOLMIUM
In this study, we created radioactive holmium via proton bombardment of dysprosium,
measured the production yields, and assessed the therapeutic potential of the subsequent
narrow-band x-rays.
The dysprosium foil target consisted of a 3 mm square cut from a 25 mm x 25 mm,
0.1 mm thick, 99.9% (REO) sheet (Alfa Aesar, USA). The foil was placed in a graphite
target holder made from a 3/8in x 6in cylindrical AXF-5Q graphite rod of density 1.78 g/cc
(Poco Graphite Inc., USA). The graphite rod is highly pure with the largest contaminant
being Ni at a concentration of 0.01 parts per million. The target holder was fabricated
into a cap with a 1.5 mm diameter hole in the face to reveal the foil as seen in Figure 2.1;
the cap threads onto the support to put the foil in thermal contact with the graphite. The
entire apparatus was then placed in a water cooled aluminum Faraday cup and attached
to the line 1 of the VUMC RDS 112 cyclotron. The bombardment was performed at ap-
proximately 10 µA of proton beam current for 10 seconds (exact charge integration will
follow in Section 2.1). Following irradiation, the activity measurements were carried out
by γ-ray spectrometry using a calibrated GMX 35P4 high purity germanium (HPGe) coax-
ial detector (EG&G Ortec, USA) and the Gamma Vision acquisition system (Version 6.01,
EG&G Ortec, USA). An Isotope Products multi-nuclide standard check source (Eckert &
Ziegler AG, Berlin, Germany) with detector geometry identical to our experiment was used
to produce a point-source efficiency calibration curve.
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Figure 2.1: Target holder assembly: 3-D depiction and 2-D cross section. The beam axis
runs from left to right.
2.1 Activity Calculation
The foil was placed in the HPGe detector and counted 41 times consecutively. To
decrease dead time, the foil was fixed approximately 25 cm from the germanium crystal.
For each run, the GAM32 analysis engine produced the background counts and net area
counts for each peak at its centroid energy as well as the percent uncertainty of these counts.
With these data for each run, the net area counts per second (corrected for dead time) were
plotted versus time for each peak and the curves fitted as a decaying exponential using the
fitting toolkit from pythonlabtools, available online(Mendenhall, 2008).
Charge Calibration
The cyclotron is not equipped with an accurate beam current integrator; to calculate pro-
duction data from the activity yields, we performed a charge calibration. The total number
of incident protons and the exact energy of each cannot be replicated precisely by additional
experiment and so the calibration must be performed concurrently with the irradiation of
the foil. To accomplish this, we used the graphite target holder as our reference. At a pro-
ton energy of 11 MeV, the reaction 12C(p,γ)13N yields 13N at a rate of 250 MBqµAhr(Krasnov
et al., 1969) or in more useful units, YC = 6.9 × 104 MBqC . Assuming a reasonably uniform
beam, the ratio of the charge incident on the dysprosium foil to that incident on the cap,
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QDy/QC, is equal to the ratio of the area of the exposed foil to the area of the exposed
carbon (graphite). The stopping range of protons in graphite is λ =
￿
(dEdx )
−1dE = 0.78 mm
(Berger et al., 2008). Notice from Figure 2.1 that this penetration depth is less than 2.5 mm,
the thickness of the portion of the cap that covers the foil. Thus, protons that did not travel
through the hole in the cap did not reach the foil and could therefore not contribute to any
production. The cross-sectional area of the foil irradiated is then the area of the hole in the
cap, so ADy = Ahole = 0.018cm2. The area of the exposed graphite cannot be observed di-
rectly, but instead we can observe the ratio of its area to the area of the hole. To accomplish
this, we performed a control experiment in which we used a small graphite sheet in place
of the dysprosium foil in our same graphite target holder; since the production yield is the
same for the graphite cap and sheet, the ratio of activities will equal the ratio of the areas
exposed to the proton beam. This ratio was observed to be γ = ActcapActsheet =
Abeam
Ahole
= QCQDy = 18.8;
the incident beam cross-section is then Abeam = 0.33cm2. The yield calculation for each
isotope, iHo, of holmium is then summarized as follows.
YDy→iHo = Y12C→13N
ActiHo→Dy
Act13N→12C
· γ
Subtleties of Graphite Activity Measurement
Since 13N has a half-life of 9.965 minutes, it was important to start measuring the
graphite cap immediately after bombardment in order to accurately count the short lived
511 keV annihilation peak. The HPGe detector would saturate and dead time would be-
come unmanageable with such a “hot” sample so shortly after being irradiated. To circum-
vent this problem, we used a Victoreen 450 Ionization Chamber (Elimpex-Medizintechnik,
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Austria) to measure the exposure rate of the cap. We observed the exposure rate every 60
seconds from 6 minutes after bombardment to 68 minutes after bombardment; data were
subsequently converted from exposure to activity (Γ= 0.0407 C·cm2kg·GBq·hr (5.84
R·cm2
mCi·hr)for
13N
in air). The internal geometry of the ion chamber, however, is complicated and the final
reading is an integral over all angles in which photons pass through the pressurized gas
chamber along with the rate at which these energy photons create ion pairs. The graphite
cap was placed close enough to get sufficient signal, but being so close, the results are bi-
ased by the geometrical uncertainties in the 1/r2 point source and detector approximation.
To correct for this geometry problem we performed another control experiment. An
18F sample from the Vanderbilt University Radiopharmacy(PETNET Pharmaceuticals Inc.,
2002) (produced daily and used for PET scans), was standardized in a dose calibrator that
directly reports the activity (in mCi) of a given sample of 18F. This particular isotope of
fluorine is a pure 511 keV source (positron emitter) with a half-life of 109.7 minutes. We
duplicated our previous geometry with the ion chamber and by measuring the exposure rate,
given the observed activity (Γ= 0.0418 C·cm2kg·GBq·hr (6.0
R·cm2
mCi·hr)for
18F in air), we can determine
r, the effective distance from the source to the detector. 18F activity was reverified at the
end of the experiment to confirm charted decay constant.
After 88 minutes (about 9 half-lives of the decaying 13N) from bombardment, the cap
was counted in the HPGe detector for 20 consecutive 60-second runs. These data were then
fitted and compared to the ion chamber data for corroboration.
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Figure 2.2: Photon spectrum for proton irradiated dysprosium: Bold plot corresponds to
left (linear) axis. Gray plot corresponds to right (logarithmic) axis.
2.2 Spectroscopic and Dosimetric Characterization
Spectroscopy
The spectrum generated by the detector software for the first of the 41 total counts
on the foil is displayed in Figure 2.2. As can be seen, we have created a clean spectrum
with strong peaks at 45 and 55 keV, and very little activity anywhere else in the spectrum.
Isotopes created were identified to be 160Ho,161Ho, and two nuclear states of 162Ho, all
of which decay by electron capture (the excited state of 162Ho decays partially by internal
transitions, see Section 2.2). Since photons emitted in EC depend on atomic structure,
and not nuclear structure, neighboring isotopes of the same element emit identical x-ray
photons. Thus, identification of photon energy is not enough to ensure that any particular
line in our spectrum does in fact correspond to a specific initial isotope; the decay of these
peaks over time must also match the half-lives of the appropriate isotope.
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161Ho decay
Gamma ray matching (both energy and decay rate) is the key to proper isotope identi-
fication for a mixed source. Consider the 25.4 keV peak associated with the 161Ho decay
depicted as set (2) in Figure 2.3. The data fit well to gamma emission produced from the de-
cay of an isotope with 149.6 minute half-life; 161Ho has a half-life of 148.8 minutes. Other
than the K- and L- x-rays that come from the EC decay, there are only two other notable
peaks, one at 77 keV and the other at 103 keV ( (11) in Figure 2.3); each fit equally as well
to the 2.5 hour half-life, and their individual abundances match the intensity differences in
the branching ratios.
162Ho decay
The 185 keV peak shows good evidence for the existence of the excited state of 162Ho,
162mHo, which decays by EC (38% probable) back into the ground state of 162Dy with a
half-life of 67 minutes. Set 5 of Figure 2.3 illustrate this decay. Again, not only do we have
the other notable peaks in the decay, (namely 282, 937, and 1220 keV) but they all fit well
to the 67 minute half-lived exponential. The 511 keV annihilation peak is evidence of the
other decay chain of 162Ho. Curve (10) of Figure 2.3 fits well to a half-life of 67 minutes
running parallel to data for the 185 keV peak (set (5)). This radiation, however, is created
in the ground state decay of 162Ho back to 162Dy, which has a 15 minute half life, but it
is populated from the 67-minute IT decay of 162mHo (62% probable) that fills the 162Ho
ground state. Recall that in a decay series where the parent isotope is longer lived than its
daughter, a transient equilibrium will be reached in which the behavior of the decay series
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Figure 2.3: Key Decay Curves. Plotted are the background subtracted, dead-time cor-
rected, net areas (in counts/sec) ±1-sigma for each of the 41 counts in the detector versus
time for several key peaks. The decaying exponential fits were generated by the modified
Levenburg-Marquardt (L-M) algorithm consisting of 50 L-M steps with the decay constant
parameter frozen followed by a single step with the decay constant as a free parameter
which produces a nonzero covariance matrix that substantiates the reduced chi-squared
value.
will mimic the half-life of the longer lived parent isotope. The 1330 keV peak exhibits the
same behavior; this along with the 38 keV peak that comes directly from the IT decay are
substantial indicators that we are in fact populating both the excited and ground states of
162Ho, and that both branches in the decay scheme of the excited state are active.
160Ho decay
The decay data corresponding to the creation of 160Ho are noisy, due to low yield, with
relatively high uncertainty. The activity has a longer decay constant (5.02 hour half-life)
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on the fringe of our detection ability in this experiment. We do, however, see a sufficient
number of 160Ho lines to have high confidence in its identification. Very few high energy
gammas are produced in the IT decay into the ground state (65% probably), while similar
dysprosium K x-rays are emitted during the EC decay (35% probable).
X-rays
The K- x-rays are at the heart of this paper, yet their time dependence is not a sin-
gle exponential, making it hard to compute nuclear yields from them. This can be easily
understood when the origins of these photons are considered. 160Ho , 161Ho , as well as
the ground state and one branch of the excited state of 162Ho decay by EC which leaves a
K-shell hole in dysprosium; the atom stabilizes by photoemission of these K- x-rays. Ac-
cordingly, there are four different sources of photons with the same energy in our system,
each of which decays at a different rate, ranging from 15 minutes to 5 hours. The majority
of the activity comes from the two holmium isotopes, 162mHo and 161Ho, and so the data fit
fairly well to a sum of exponentials, one with 67 minute half-life and one with 149 minute
half-life; the curves (2) and (4) (running through sets (1) and (3)) of Figure 2.3 show these
2-component fits. With the counting statistics available, we cannot meaningfully fit a sum
of four exponentials (8 free parameters) on only 41 data points, so we present our data as
shown. Since the short-lived component decays too quickly to be relevant for applications,
and the long-lived one has too low activity to be germane, their omission is inconsequential
to the results, but account for the slight imprecision in the fit.
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Charge Calibration
The exposure rate of the graphite cap was recorded every 60 seconds for 62 minutes
and the results are plotted as set (13) in Figure 2.3. The half-life of 10.3 minutes can be
easily identified as the β+decay of 13N into 12C. Immediately after measuring the cap with
the ion chamber, it was brought to the HPGe detector and counted as described above; the
energy of the nitrogen decay was confirmed as annihilation radiation. The spectrum of
the cap in the detector revealed only one contaminant, 60Cu, probably originating from the
trace amount of Ni present in the natural carbon. The 60Cu decay, consisting of three higher
energy gammas (826, 1332, and 1790 keV) along with a 511 keV annihilation peak, are
easily identified and fitted to the 23.7 minute half-life. 11C, a pure positron emitter having
a 20.4 minute half-life could also have been created by the plausible (p, pn) reaction, but
would be indistinguishable from the 60Cu decay. We fit the annihilation peak data to a
double exponential to pick out the two half-lives. Set (14) in Figure 2.3 shows the detector
data and curve (15) connecting both cap data (ion chamber and detector) is the fit to a sum
of decaying exponentials, one with the 9.965 minute half-life of 13N, the other with the
23.7 minute half-life of 60Cu. Once corrected for efficiency and branching ratios the fit
yields 11.36 MBq of 13N. From this we find the incident charge on the cap QC = 160µC.
Production Yields
Results for the key peaks are tabulated in Table 2.1. Some of the peaks come from two
different isotopes or different nuclear states of the same isotopes; for this reason, not every
value for total nuclei of the same isotope created matches. What we can see however, are
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Table 2.1: Total production for the key peaks in the spectrum. Isotopes listed identify
which branching ratio was used in calculation. Note that the yields are not weighted by the
isotopic composition of natural dysprosium because we can not differentiate the production
channels of each isotope.
Eγ (keV) Ho isotope Peak Activity ±1σ (kBq) # Nuclei (×108) Yield (GBq/C)
25.41 161 70.8± .5 9.2 8.2
45.21 161 120.1± .7 † 14
45.99 161 59.5± .4 † 6.9
52.11 161 139.1± .9 † 16
80.7 162 94.4±2.2 4.9 11
86.49 160 1.61± .05 0.41 0.19
103.04 161 59.8± .9 7.8 6.9
184.85 162 29.5± .4 1.7 3.4
196.88 160 1.21± .05 0.31 0.14
282.84 162 31.6± .6 1.8 3.7
511.17 162 54.0±2.3 3.2 6.2
728.3 160 1.37± .06 0.36 0.16
937.29 162 40.1± .2 2.3 4.6
1220.1 162 42.6±1.1 2.3 4.9
1312.6 162 24.9± .2 1.4 2.9
† For the x-rays, the 148.8 minute half-life component has been separated in the double
exponential fit and used to isolate the 161Ho, but the multiple origins of these photons
renders the calculated number of nuclei created inaccurate.
the matching peaks corresponding to the same decay chains. Notice, for example that the
184, 282, 937, and 1220 keV peaks, which all come from the 67- minute decay of 162mHo
into the ground state of 162Dy, all have similar values for the total number of nuclei created,
a weighted average of approximately 2.2×108 nuclei of 162mHo. Also, the 25 and 103 keV
peaks, which come from the 2.48 hour decay of 161Ho into 161Dy, both count the similar
number of 161Ho nuclei created, the weighted average being 8.8× 108 nuclei. The 80.7,
511, and 1320 keV peaks illustrate the 15-minute ground state decay of 162Ho into 162Dy.
There are several sources of error in these numbers. First, the 80.7 keV peak comes from
the decay of both the excited state and ground state of 162Ho and so there are two decay
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constants and two branching ratios that are not separated out in this table. We may have also
populated the ground state directly at bombardment, so the true origins of these three peaks
cannot be accurately determined, which is why their activity does not serve to precisely
estimate the number of nuclei created. The important things to take from these data are
the orders of magnitude involved. We have made approximately four times more 161Ho
than the ground and excited states combined of 162Ho and a factor of 24 more 161Ho nuclei
than 160Ho, the longest lived contaminant (3.6× 107 nuclei). Furthermore, even though
there are some higher energy gammas coming from the 160Ho decay at the percent level,
this decay contributes even more of the same, low-energy x-rays. So too does the decay of
162Ho, which because of the shorter half-life is even less detrimental as a contaminant. For
analytical purposes we use the individual gamma rays as a standard to see the total number
of each isotope created, but for applications, the amount of high energy contamination is
overshadowed by the significantly higher number of useful, low-energy x-rays.
An important note on error analysis: as you can see from the activity error bars (which
consist of propagating the detector’s counting statistics and the fitter’s Poisson statistics) we
have clean, distinct peaks that fit very well to decaying exponentials. The values calculated
from these activities, such as nuclei created, and production yield, all depend on the carbon-
nitrogen yield found in Krasnov et al. (1969). In this paper, Krasnov quotes the “total error
of the resulting isotope yield values was ±10%”, which if were correct, would propagate
through and dominate the small statistical error, and so all further calculated values would
have 10% error.
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Reaction Channels
The work presented here does not contain sufficient information to uniquely identify
the nuclear processes that yield the various nuclides. However, it is possible to make some
general considerations which can suggest possible improvements to the yield based on the
isotopic composition of the parent material.
We have carried out nuclear modeling using the CEM03 nuclear physics code (Mash-
nik and Sierk, 2002). This code is primarily intended for protons above 100 MeV, but
discussion with its authors has led us to believe that it is still reasonable at much lower
energies. These calculations have shown that (p,n) and (p,2n) reactions are likely, with
(p,n) being the dominant channel. Accordingly, 161Dy is probably the most important par-
ent isotope, and since it is only 19% abundant in natural dysprosium, one could improve
the yield significantly by starting with enriched material. That being said, even with the
natural dysprosium foil, we have generated plenty of x-rays to use therapeutically and very
few contaminants, making this technique cost efficient and practical.
Therapeutic Relevance
The air kerma rate constant for 161Ho in SI units is 19.9cGy·cm
2
GBq·hr (0.74
cGy·cm2
mCi·hr ). Rates for
the other isotopes produced can be calculated similarly, but since the spectrum is dominated
by 161Ho and the gamma intensity produced in the 162Ho decay will decline substantially
during transport to a patient, this is the most predictive measure of the dose deposition.
Given a proton energy of 11.6 MeV and a beam current of 50µA we can produce 161Ho at
a rate of 0.023GBqmin (0.61
mCi
min ). It is important to note that the holmium will decay during
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Table 2.2: Dosimetric profile and modestly estimated production capabilities of 161Ho.
Values are compared to commercially available model 6711, 125I Oncoseeds.
Initial Integrated Dose
Air Kerma Production Available Dose Rate @ 0.5 cm
Nuclide RateConstant Rate Activity @ 0.5 cm after 12 hours
b
Γ(cGy·cm
2
GBq·hr )
￿
GBq
min
￿
(GBq) (cGyhr ) (cGy)
161Ho 19.9 0.023 1.8a 148 540
125I 35.7 - ≤0.37 perseed 53 640
aActivity produced after 3.6 hour bombardment at 50µA.
b96.5% decay of a 2.48 hour half-life source will occur after approximately 12 hours or
overnight.
longer irradiations so for irradiations longer than the mean lifetime of the isotope (3.6
hours for 161Ho) production will saturate. After 3.6 hours, then, we can make 1.8GBq
(48.7mCi), which at a treatment distance of 0.5 cm will deliver 540 cGy of air dose. For
comparison, we have included similar calculations for model 6711, 125I Oncoseeds (Oncura
Inc., Plymouth Meeting, PA).
2.3 Engineering Advances
Important to keep in mind are the equipment and facilities used in this study relative
to the state-of-the-art. Figure 2.5 depicts the evolution of our target holder designs. The
first generation (schematics of which are pictured in Figure 2.1) was designed for very low
current and beam time. This was the apparatus used in the spectroscopic characterization of
the radiation induced during bombardment. The graphite was sufficient in dealing with the
minimal amounts of heat during these short (~10 second) cyclotron runs and also provided
the useful framework for the charge calibration as discussed in Section 5.5.
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The second generation introduced some water cooling to withstand longer bombard-
ments. In consisted of a copper core through which chilled water circulated, carrying heat
away from the foil. The foil was situated on the flat tip of the copper rod and fastened in
place by a graphite cap that threads onto the copper. The aluminum shell simply couples
the entire apparatus to the cyclotron and sustains the vacuum level. Several graphite caps
were experimented with to optimize beam transmission, structural integrity, and heat con-
trol; the “pepper shaker” design was used most frequently because of the ease in handling
and the condition of the foil upon extraction after its use.
For in vitro irradiations, the third generation target assembly was designed and imple-
mented. Since much longer and higher-current bombardments were necessary to deliver
sufficient activity, and therefore dose to cells, the cooling system needed to be improved to
allow for full beam transmission with no foil degradation for several hours. This generation
combined water- and helium-cooling. The front (beam-in) face of the target assembly is
solid with a hole along the beam axis one centimeter in diameter (more than twice the ~4
mm beam diameter) that exposes the front face of the foil, both sides of which were cov-
ered and baked in silicone to ensure complete vacuum seal and prohibit any contamination.
There is a rubber O-ring that sits in an etching on the back side of the front face which
keeps a vacuum seal between the foil and this face. In fact, the foil acts as the window and
keeps an air-tight seal from the front face to anything farther down the beamline. This is
crucial since the back of the foil is to be cooled by a constant flow of helium, which is a
fairly inert gas, but which could still cause damage to the cyclotron if this seal were broken
(actually when the vacuum is lost (pressure ￿ 1 mPa), one of the many safeguards of the
cyclotron is automatically activated and the machine is immediately shut down).
33
The helium is pumped through a thick washer that has a small passage bored out per-
pendicular to the beam axis. The holes in the washer are aligned with the pathways in the
outer brass housing so that the helium flows through to the opening in the middle disk.
This opening is sandwiched air-tight between the back face of the foil and the front face of
the water-cooled, aluminum backing that is fastened in thermal contact to the middle disk.
Chilled water is circulated through the aluminum back, which in turn cools the disk. Since
the center of the disk is cut out (the same diameter as the front hole), virtually none of the
beam’s energy is deposited in it, and so it remains chilled and serves to cool the helium
even further as it flows. The chilled middle disk also serves to cool the part of the foil not
exposed to the beam through the front hole.
We used a thin (100 micron) foil since the stopping range of protons at this energy is
about 400 microns. The production cross section decreases substantially as proton energy
decreases and so after the first 100 microns, the beam would probably do more to heat the
foil than increase the production yield.
As an estimate, we performed a Coulomb-apsis calculation to determine the approxi-
mate energy dependence of the production cross section. At an energy of 11.6 MeV, as-
suming a reasonable cross section (the average value from the Shen, Tripathi, and Tripathi
(light reactions) calculations of the total reaction cross section is σ ≈ 340mb (Tripathi
et al., 1997, 1999; Shen et al., 1989)) we can calculate the distance of closest approach
of the proton to a dysprosium (Z= 66) nucleus considering only Coulomb repulsion. Let
the distance of closest approach be rmin and the corresponding speed of the proton be vmin.
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Conservation of energy (neglecting nuclear recoil) yields,
E =
1
2
mv2min+
Z1Z2ke2
rmin
. (2.1)
Conservation of angular momentum relates the impact parameter b to rmin:
mvb= mvminrmin. (2.2)
The kinetic energy of the proton then becomes
E =
1
2
m
￿
vb
rmin
￿2
+
Z1Z2ke2
rmin
. (2.3)
The solution for rmin is
rmin =
α
2E
+
￿
α2
4E2
+b2 (2.4)
where α = Z1Z2ke2 = 66×1.44MeVfm and σ = πb2. Inverting this relation we solve
for b and ultimately the cross section, σ , as a function of E with our calculated rmin as a
constant.
σ(E) = πb2 = π
￿
r2min−
αrmin
E
￿
(2.5)
The results of Equation 2.4 yielded rmin = 9.35fm. The more detailed calculations of
Tripathi et al. (1997, 1999); Shen et al. (1989) , which include geometrical and charge
screening corrections, agree on a slightly different result (i.e. rmin = 9.68fm) for the
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Figure 2.4: Energy Dependence of Production Cross Section. Top axis models the depth at
which the beam will have the corresponding energy (bottom axis).
Coulomb barrier. We corrected the cross section to vanish at their value of the Coulomb
barrier, and plotted Equation 2.5 as a function of proton energy in Figure 2.4, along side
the Tripathi formula. The top axis models the depth at which the beam, initially at 11.6
MeV, will have the corresponding energy labeled on the bottom axis. These values were
calculated by integrating the stopping power for protons in gadolinium (7.9 g/cm3, the
closest analog to dysprosium on the PSTAR database) in 10µm intervals(Berger et al.,
2008). Here we can see that after a depth of about 95µm, the cross section drops by an
order of magnitude and vanishes completely before 110µm.
To test this idea, we attempted to perform a short, low-current bombardment with two,
100 micron foils sandwiched together and measure their activity. The experiment failed
because the heat transport was so bad that the two foils nearly melted; they fused to each
other and to the target holder rendering the result useless. Instead, we repeated the same
experiment with a single 250 micron foil followed by a single 100 micron foil. After
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bombardment, each foil was placed at a fixed distance from an ion chamber and their
exposure rates were recorded; the graphite caps used in each bombardment were treated
similarly since, especially for shorter bombardments, the charge of protons incident on
the target is not well reproducible. The ratio of each’s exposure rate to its corresponding
cap was compared. The results were as expected: the two foils had virtually identical
production. Using the thinner of the foils would therefore decrease the amount of heat
deposited in the foil, facilitating the cooling process. With this combination of water- and
helium-cooling of a thinner foil, we were able to run the cyclotron at 30 µA for 3 hours
without compromising the structural integrity of the foil.
The VUMC cyclotron operates at a maximum of 50 µA and delivers protons with nomi-
nal energy of 11.6 MeV. By the industry standard, this machine is obsolete; nonetheless, we
are able to produce sufficient activity to be useful therapuetically. Looking forward, though,
the radiopharmacy is in the process of upgrading to a PETtrace 100 (General Electric); an
unshielded, 100 µA machine that will deliver protons up to 16.5 MeV (and deuterons up to
8.5 MeV). By the same approximation as above we find that the cross section will increase
by a factor of three at this energy, and so this increase in proton energy alone will boost
the yields. The increase in beam current, after some clever engineering in target-cooling
design, will also inflate the yields. The results will both decrease the beam time (and there-
fore cost) to produce sufficient activation as well as relax the rush in transport currently
necessary to provide sufficient activity to the patient.
A new, low-energy, narrow-band x-ray source would be uninteresting without its appli-
cation in mind. We will show, however, that 161Ho, having an energy spectrum centralized
at the peak of iodine absorption, succeeds in exploiting the synergistic potential of photon
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Figure 2.5: Evolution of target holder design.
activation therapy and this combination will become a more efficient technique in radiation
oncology.
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CHAPTER III
SENSITIZATION DEFINED
There is a need to appropriately and objectively measure sensitization based on fun-
damental physical processes. In the majority of literature, researchers define one of two
forms of a sensitization enhancement ratio (SER): horizontal and vertical. For vertical ra-
tios, given a particular dose, the SER is defined as the ratio of surviving fraction in the
control curve to that of the drug curve (i.e. SER2Gy). Horizontal values are given as the
ratio of the dose required to kill a given surviving percentage in the control group to the
dose required in the drug group (i.e. SER10%). Both of these quantities give an idea of
sensitization but both depend strongly on the chosen value of dose or surviving fraction at
which to measure. In fact, the vertical SER is exponentially dependent on the choice of
dose, and it can be derived analytically:
SERd =
e−α2d−β2d2
e−α1d−β1d2
= e−(α2−α1)d−(β2−β1)d
2
(3.1)
where the surviving fraction, S, is related to dose, d, according to the linear-quadratic
model S = e−αd−βd2 . Many researchers pick 2 Gy for its practical value (in fractionation
therapy, 2 Gy is the usual prescription for a fraction), but otherwise this choice is arbitrary.
Similarly, researchers often pick 10% survival, but different shaped curves yield wildly
different ratios at different surviving levels. In Section 3.1, we construct a unified, objective
way to quantify total sensitization and understand its implications in the radiobiology.
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3.1 Mechanisms of Sensitization
Dose Enhancement Ratio (DER)
We need to develop the machinery to translate the radiation survival effects into physical
mechanisms of sensitization. One major reason for effectiveness of IUdR is the fact that
iodine, being much higher-Z material than water, absorbs radiation more effectively than
water. The ratio of absorption coefficients peaks just above the K-edge of iodine, but is
apparent throughout the x-ray energy spectrum. In any case, given the radiation spectrum,
we can calculate how much more dose is absorbed in an iodinated medium than in water.
To do so we started with the total number of photons at each energy in the radiation source.
From NIST’s XCOM database we collected the full mass-energy absorption coefficients
(µenρ )E of air, water, and iodine, and interpolated these values at the energies of our radiation
spectrum. The DER is then simply calculated as
DER=∑
w(µenρ )
iodine
E +(1−w)(µenρ )waterE
(µenρ )
water
E
(3.2)
summed over all energies in the radiation spectrum, where w is the fraction by weight
of the iodine in the mixture. It is generally recognized that the primary radiosensitive
sites in the cell lie within the nucleus (Hofer et al., 1993; Roa et al., 1990; Narra et al.,
1994) and so even though the DER of the whole cell may be greater, only the enhanced
absorption in the nucleus will manifest itself in radiosensitivity. We calculated the total
number of iodine atoms per nucleus from the observed moles of thymidine, moles of iodine,
grams of DNA, and number of cells for each measurement in the incorporation experiments
mentioned earlier in Section 4.3. Using confocal microscopy (LSM710, Zeiss) combined
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with a Hoechst staining of the nuclei (Hoechst 33342, Invitrogen #H1339), we measured
the size of the nucleus; assuming the nucleus is a sphere of water, we calculated the volume
and therefore the mass of water in the nucleus. From this we determined w and calculated
the nuclear DER for each of our radiation sources.
Now we need to understand how this dose enhancement will manifest itself in the sur-
vival effects. Thus far we have ignored any radiobiological or chemical effects IUdR might
have on the nuclear DNA. The benefit of isolating the mechanisms of sensitization will
become more apparent later. The only thing we have included in the calculation of DER
is the fact that there is different absorption in iodine relative to water. Figure 3.1 is a con-
ceptual figure of merit that should help to visualize the effect of a DER on the survival
curve. The DER tells us that for the same air-dose (external fluence) of radiation, iodinated
nuclei will absorb an added dose. By measuring the control (no drug) response, we have
observed how an increase of dose will affect the radiation survival of the same type of cell.
So a new point (C) that is at the same surviving percentage as the dose-enhanced point B
but at an unchanged air-dose, d1, is now on a curve for cells that have the same radiobi-
ological properties, but whose nuclei simply absorb more dose than equivalent cells with
no drug. We can see that the DER is not just a constant separation between the drug and
no-drug curves but rather an more rapid progression along the no-drug curve. This DER
is a function of the difference in absorption spectrum at all energies and as such, is dose
independent. We can calculate this new survival percentage, S2, at every dose and generate
the new curve, both graphically and analytically. The surviving percentage at points (B)
and (C) are the same: e−α1·DER·d−β1·(DER·d)2 = e−α2d−β2d2 = S2 and so solving for α and
β we are left with α2 = DER ·α1and β2 = DER2 ·β1. Again, this DER value and this new
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Figure 3.1: DER Visualization: A) point on control (no drug) curve at (dose, Surviving
fraction) = (d1,S1). At same air-dose, iodinated nucleus absorbs d2 = d1 ·DER whose
surviving fraction is measured to be S2 at point B. Iodination added dose without changing
external fluence so drug curve goes through point C which has surviving percentage of B
but air-dose of A. Similar progression from points C to E occurs from added dose due to
ISI restabilization cascade.
survival curve isolates only one phenomenon: radiation is absorbed better in iodine than in
water. It only takes into account the fact that there is a difference in absorbing material in
the drug-containing cells relative to the control. The effect would be the same if iodine was
used as a contrast agent in the nucleus and not specifically bound to anything important
(i.e. DNA) in the nucleus. We must next isolate another mechanism of sensitization and
understand what happens to iodine when it absorbs a photon.
42
Inner-Shell Ionization (ISI)
From the number of iodine atoms per nucleus and the number of cells per dish, we can
use the photoelectric absorption cross-sections for iodine (Berger et al., 2005) interpolated
at each energy in the radiation spectrum to calculate the total number of photoelectric events
per incident photon at each energy. Using the mass-energy absorption coefficients for air we
can sum over the whole spectrum and calculate the air-dose from the number of photons at
each energy. This was also used later to validate the fluence and dose rate of each radiation
source. Knowing the exact number of photons of each energy per dose of radiation we can
calculate the total number of photoelectric events per unit dose.
The second mechanism of dose enhancement is activated after an inner-shell ioniza-
tion of iodine, when the electrons reorganize themselves back to the ground state, and emit
fluorescent (characteristic) x-rays and Auger electrons. Figure 3.2 shows Monte Carlo sim-
ulation results for the Auger spectrum of stable iodine after an ISI(Karnas et al., 2001).
From the left plot we can see that number of electrons per ISI ranges from none (for a
purely fluorescent event) to approximately 40 for an intense K-shell initiated Auger cas-
cade, the average being nine. The variation in number and energy of the electrons among
different cascades makes it difficult to calculate the dose and so we need a way to model
this phenomenon and quantify the dose of radiation per ISI.
An appropriate model is 127Xe which as it decays by electron capture (EC) to 127I is
left with an inner-shell vacancy just like stable iodine after being K-ionized. Goddu et al.
(1997) have used Monte Carlo simulations to calculate the self-absorbed dose per unit
cumulated activity, “S-values” for selected radionuclides including 127Xe. Several source
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a) b)
purely fluorescent event, up to approximately 40 elec-
trons for an intense K-shell Auger shower. The average
cascade size was determined to be 9 electrons, which is
in good agreement with estimates obtained for radioac-
tive 123I which undergoes a single electron capture event
and thus has similar vacancy filling [17].
Figure 3b shows yields of simple and complex DSB
(sDSB and cDSB) per K-shell Auger cascade size. Ex-
cept for the smallest size cascades, the likely outcome of
an Auger event is a complex DSB. The probability of
producing a DSB (simple or complex) reaches near unity
for cascades of 20 electrons or more. The DSB expecta-
tion values are (Fig. 3c) for K-shell vacancies, a product
of the DSB yield per cascade (Fig. 3b) and probability of
an Auger cascade of a particular size occurring (Fig. 3a).
The DSB expectation value represents the probability of
getting a DSB from a particular size of Auger cascade,
given a K-shell vacancy. Thus, although cascades of 20
or more electrons are very effective in producing DSB,
they occur infrequently and therefore have a low DSB
expectation value. The maximum expectation value oc-
curs for approximately 9 electron cascades, with a value
of approximately 0.027 DSB per K-shell vacancy. By in-
tegrating the curve, the total DSB expectation for all
possible burst sizes was determined to be 0.30, which is
in reasonable agreement with 0.4 DSB per 123I decay,
which produces a similar Auger cascade [15].
For a full analysis of photoelectric events in the io-
dine atom, the Auger cascades that originate in other
electron orbitals must to be considered. The average
numbers of emitted Auger electrons for different initial
vacancies are illustrated in Fig. 4a and range from 10
electrons for the L1-shell orbital to approximately 3 elec-trons for the N-shell orbitals. There is an increase in the
average number of electrons emitted from the L1-shellcompared with the K-shell because of the nature of the
atomic relaxation process. A K-shell vacancy has a high
probability (88%) of being filled through a fluorescent
event, which effectively moves the vacancy to an outer
orbital (i.e. L, M, etc.). This will result in a fluorescent
x-ray and a “smaller” Auger cascade initiating at this
new, lower energy vacancy. In contrast, an L-shell va-
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Fig. 1 Electron depositions from a a segment of a 10 keV electron
liberated in water, b a 2-electron N-shell Auger cascade, c a 5-
electron M-shell Auger cascade and d a 10-electron K-shell Auger
cascade. The individual electron tracks from each Auger electron
are illustrated using a different symbol and the DNA model is il-
lustrated in the for reference (scale in µm)
Fig. 2 The energy spectrum of the emitted Auger electrons from
iodine atoms with a K-shell vacancy. The main graph is the spec-
trum between 0 and 33 keV (0.1 keV bin size) while the inset
shows the low energy (<1 keV) electrons with higher resolution
(0.01 keV bin size). The spectra are normalized to unity for the to-
tal number of electrons emitted with the main graph's y-axis trun-
cated (0.1 keV line is approximately 0.6) to illustrate the low tran-
sition probability lines
Fig. 3 a The burst size distribution of the Auger cascades in terms
of the number of electrons emitted per K-shell vacancy. This
graph is normalized such that the total probability is unity (i.e. ar-
ea under the curve) for a cascade of any size. b The DSB yield is
the probability of producing a DSB in the DNA given a K-shell
cascade and is shown here as a function of Auger burst size. c The
DSB expectation values per Auger burst from K-shell vacancy for
different Auger cascade sizes. The DSB yield per K-shell vacancy
is the area under the curve (0.3) for all Auger burst sizes
Figure 3.2: a)Histogram of the Auger distribution in ter s of number of electrons ejected
per initial K-shell vacancy in iodine (normalized to unity). b)Energy spectrum of emitted
Auger electrons. (normalized to unity; 0.1 keV bin is truncated in main graph, but expanded
in inset) Both plots from Karnas et al. (2001).
to target regions are tabulated, but for radiobiological purposes the nucleus is the most
important target volume. We have measured in detail in Section 4.3 how much iodine is
taken up in each compartment of the cell and so can c l ulate the tribution of dose from
each source volume to the nucleus. Values are given as dose per disintegration of 127Xe,
which is equivalent to dose per ionization since during one EC decay, there is one K-shell
vacancy. Thus, since we have calculated the total number of photoionizations in each target
volume, we have an estimate of the added dose to the nucleus from each.
This addition of dose will this manifest itself similarly on the survival curve because the
number of photoionizations increases linearly with external dose; the number of incident
photons for a given radiation source is proportional to the dose. The added dose at any
point will be the added dose per Gy times the dose at that point. Starting with our second
curve generated after the DER calculation we have the surviving percentages, S3, for our
new curve.
S3 = e−α2(d+dadd/gy·d)−β1(d+dadd/gy·d)
2
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= e−α3d−β3d
2
(3.3)
where
α3 = (1+dadd/gy) ·α2
and
β3 = (1+dadd/gy)2 ·β
Again, the same cells, with the same radiobiological properties, simply absorb extra dose,
and we have already measured how cell survival relates to the addition of dose in the con-
trol. We have isolated and quantified two mechanisms of dose enhancement, neither of
which takes into account any sensitization of the cell survival due to a foreign object at-
tached to nuclear DNA. It is important to note that given an accurate measurement of in-
corporation of iodine into the different cellular compartments, this calculation will yield
the minimum total sensitization. This concept is a useful check of the accuracy of incorpo-
ration measurement, and will be revisited later when comparing our results to those in the
existing literature. Now we have to consider the effect of the higher-LET radiation that is
emitted upon de-excitation (Auger and fluorescent emission) on cell survival.
Quantifying the Quality of Radiation
Notice that up to now the addition of dose to the nucleus has increased both α and
β . α is a measure of intra-track, non-repairable lesions to the DNA, stemming from
multiple energy depositions from the same ionizer, while β is a measure of inter-track,
repairable lesions to the DNA, stemming from multiple energy depositions from different
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ionizers(Fertl et al., 1984; Chapman, 1980; Malaise et al., 1987). Higher-LET radiation,
by definition, is more densely ionizing and so we expect α to increase compared to low
LET radiation; in general, the ratio of repairable lesions to total lesions will decrease with
increasing LET. That is not to say that number of repairable lesions will decrease, because
the total number of lesions will increase. The contribution of repairable lesions to total
cell survival, however, should decrease with increasing LET. A measure of this effect is
α/β which has units of dose; this is the dose at which both types of lesions have equal
contribution to cell killing/survival. We expect this ratio to increase with increasing LET.
In our case, all of the incident radiation is considered low LET, but the radiation coming
from the de-excitation of the ionized iodine is much higher LET (low energy photons and
electrons). The hypothesis is that an increasing number of ionized iodine atoms should
result in more high-LET radiation, and that if this high-LET radiation originates in close
proximity to the nuclear DNA, we should see an α-dominant survival curve. This effect
should manifest itself in two ways: first, an increase of alpha (∆α) proportional to the
amount of high-LET radiation that originates within an effective range of the nuclear DNA;
and second, an increase of α/β from the drug- to the control-curve.
Recall that according to the mechanisms defined in Sections 3.1 and 3.1 the ratio α/β
will decrease because β is increasing as the square of the dose enhancement in both cases
while α increases linearly. Observation of an increase of α/β would then validate the ne-
cessity of isolating dose enhancement from radiosensitivity.
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CHAPTER IV
PHARMACOLOGY AND IN VITRO PREPARATION
4.1 Brief History of IUdR Usage
The use of the halogenated pyrimidine, iododeoxyuridine (IUdR), as a radiosensitizers
has fallen in and out of favor since its original proposal in the 1950’s for a variety of reasons
ranging from chemical and physical to practical. Pharmacological issues have included
insufficient thymidine replacement, stand-alone cytotoxicity, and lack of specificity of drug
uptake in the tumor. Radiosensitization requires a substantial contrast of both drug uptake
and radiation absorption in the tumor relative to healthy cells. In attempts to increase
the uptake of IUdR, increases in drug concentration had exceeded toxic levels, thereby
rendering this type of therapy futile. Tumor proliferation rates far exceed those of normal
tissues in most cases, but for some fast growing cell types (e.g. bone marrow and intenstine)
uptake has resulted in cytotoxicity, again defeating the purpose of the technique. Also, in
vivo, unincorporated iodine is taken up in the thyroid and accumulates in the liver. This is
the main pitfall of using radioactive 125IUdR, which provides highly specific irradiation of
tumor cells with the advantage of depositing all of its dose in close proximity to the nuclear
DNA and so proving effective in vitro, but whose accumulation of dose in the liver proves
harmful. Fortunately, researchers have come up with clever ways to increase incorporation
while limiting cytotoxicity (e.g. thymidylate synthetase (TS) inhibitors block the pathways
of de novo synthesis of thymidine, thereby forcing the cell to use the IUdR pools during
replication), and so incorporation of stable IUdR has reached useful levels.
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There has also been a problem efficiently activating the drug once it is incorporated.
The mechanism of activation of IUdR requires an ionization of the iodine atom. This
simple concept is of paramount importance when understanding what kind of radiation is
necessary to provide not only sufficient activation of the drug, but significant contrast to
surrounding healthy cells. Synchrotron experimentation has been performed to confirm
what is already well understood physically (illustrated in Figure 4.1), that iodine is ionized
most efficiently just above its K-edge (33 keV), and the peak of the absorption contrast
relative to water occurs slightly higher in the spectrum at ~50 keV (Corde et al., 2004). At
these energies, nearly all of the interactions are photoelectric, resulting in an inner-shell
ionization (ISI). The resulting cascades of characteristic x-rays and Auger electrons are the
powerful ionizers from which this type of therapy first attracted interest. These are simi-
lar to appealing effects of 125IUdR therapy, but photon activation accentuates the synergy
between radiation and sensitizer; unlike radionuclide therapy, there is only moderate tox-
icity (if any) where only the drug (or only the radiation) is present. By using low energy
activation sources below the K-edge of iodine (e.g. 125I, and 103Pd) or high energy sources
where interactions are almost exclusively Compton scattering (e.g. 60Co, and MV x-rays),
neither enhanced ionization nor absorption contrast is exploited. Broadband sources mask
this enhancement because only a fraction of their spectrum lies in this sensitive region,
while the rest deposits dose nearly equally in cells with or without the drug. In this study,
we combine 161Ho, a radionuclide with the appropriate energy spectrum centralized at the
peak of absorption, with the iodinated drug in order to optimize the radiosensitization per
unit dose of radiation.
In this study, radiation survival of HT-29 cells is measured in vitro after radiation with
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Figure 4.1: Mass absorption coefficients for water and iodine (left (log) axis) vs photon
energy as well as their ratio (right (linear) axis). Also pictured is the scaled spectrum of
radioactive holmium created as discussed in Section 5.2.
125I seeds, radioactive holmium, 300 kVp x-rays, and 137Cs. A detailed analysis of dose
deposition, in conjunction with the survival curves of each source will precede a discussion
of the underlying radiobiology. Appropriate sensitization quantities will be reported for
each to identify optimal photoactivation source.
4.2 Tumor Cell Line
Human colorectal adenocarcinoma (HT-29) cells (ATCC Catalog No. HTB-38) from a
44 year-old Caucasian female were maintained inMcCoy’s 5aMedium (ATCCCatalog No.
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30-2007) supplemented with 10% v/v fetal bovine serum (ATCC Catalog No. 30-2020).
Incubation was controlled at a humidified 95% air-5% CO2atmosphere at 37◦C. Cells were
grown in T-75 flasks, plated at a density of 2×104 cells/cm2, and passaged every 4-5 days
(near 80% confluent); at this density cells would reach confluency in approximately 6 days.
For irradiation, cells were plated in a 24-well multi-well plate (CellBIND #3337, Corning
Inc., Corning, NY) in 0.75 mL of medium per well. This cell line was chosen for its noted
radioresistance (Miller et al., 1995; Kinsella et al., 1996). Progress towards radiation-
induced cell killing on this line should boost clinical interest in our method beyond merely
academic.
4.3 IUdR Incorporation Studies
Of paramount importance in quantifying sensitization enhancement is the accurate mea-
surement of the number of thymidine bases replaced by IUdR. Initially, two experiments
were done to test incorporation of IUdR into nuclear DNA. In the first, cells were plated in
T-25 flasks at various densities ranging from 1−4×104 cells/cm2 . On the second day, each
flask was exposed to 10µM IUdR. On the third, fourth, and seventh day (i.e. 1, 2, and 5 day
exposure), one subset of two flasks was harvested, trypsinized, centrifuged, flash frozen in
liquid nitrogen, and stored at −80◦C until all flasks were harvested. DNA isolation was
performed (GenElute Mammalian Genomic DNA Miniprep Kit, Sigma #G1N70(Sigma-
Aldrich, 2009a)) on the eighth day and the density of DNA in each sample was verified
by spectrophotometry. For one flask per subset, DNA was dissolved in 3% HNO3(the pre-
ferred buffer for ICP-MS, see below). For the other flask, the sample was split into two
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and dissolved at different densities (one twice the other) as a cross check for factors of
two in the results. Also included was a baseline standard of 3% HNO3buffer as well as a
control standard of iodine containing 0.5 nM iodine. Samples were sent to the Chemical
Analysis Laboratory at the University of Georgia (cal.uga) for inductively coupled plasma-
mass spectrometry (ICP-MS). The second experiment was performed with each flask plated
at the same density, but each exposed to a different concentration of IUdR ranging from
1−100µM. Cells were harvested after two day exposure and handled similarly.
Another necessary detail is the knowledge of where the IUdR is incorporated in the
cell. Iodine atoms in other cell compartments will affect the sensitization and therefore the
survival characteristics, and so measurement of iodine in the whole cell and cell nucleus
would be performed. Cells were exposed to a drug concentration of 20µM IUdR for two
days. A subset of the cells was simply washed twice with PBS and vortexed in the 3%
nitric acid buffer. Another subset was subject to nuclear isolation (Nuclei Isolation Kit:
Nuclei EX Prep , Sigma # NUC-101 (Sigma-Aldrich, 2009b)), and complete segregation
of the nuclei was verified by microscope. After centrifugation in step 4 of the protocol, the
supernatant containing the cytoplasmic components including light (plasma membranes,
and endoplasmic reticulum) and heavy (mitochondria, lysosomes, and rough endoplasmic
reticulum) membranes was saved, dissolved in buffer, and sent along with the whole cells
and isolated nuclei (also in buffer) to the chemical lab to further cross check the yields of
the protocol.
Growth curves for HT-29 cells with and without exposure to IUdR are plotted in Figure
4.2. The cells conformed to exponential growth after a 1-2 day lag period, the time needed
to adhere to the dish and begin signaling. Data points taken after this lag period (which can
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Figure 4.2: Growth Curves
be seen as the time-offset of the y-intercept) were fitted and doubling times were calculated
to be 24 and 48 hours for control cells and cells exposed to 20µM IUdR, respectively.
Incorporation of IUdR into isolated, nuclear DNA is illustrated in Figure 4.3 as thymi-
dine replacement percentage plotted against exposure time and drug concentration. Avail-
able thymidine sites were calculated from spectrophotometry of the isolated DNA, as-
suming 1:1 ratio AT to GC pairs and a value of 9.78× 108 base pairs per picogram of
DNA(Dolezel et al., 2003; Cavalier-Smith, 1985). Optimum incorporation was found to
be 7.3% of available thymidine sites resulting from two-day exposure to 20µM IUdR. As
expected, incorporation is greater after two days than after one day exposure; substitution
should be largely unifilar after one DNA replication, and at least partially bifilar after the
second(Fornace et al., 1990; Lawrence et al., 1990). This bifilar effect is confirmed by the
factor of 1.6 increase of substitution after the first day of exposure. Exposure beyond two
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Figure 4.3: Incorporation vs time and drug concentration. Data are corrected for baseline
and detector efficiency based on control samples.
doublings and to drug concentrations above 20µM introduced significant growth inhibi-
tion and cytotoxicity. Dead cells were washed away with PBS, so cells up-taking a toxic
amount of drug were killed and therefore not included in the measurement. We interpret
the decrease in incorporation to be a consequence of the diminished number of viable cells.
Results of the compartmental measurement of iodine are shown in Table 4.1. These
results bring about two important points: first, if the DNA is not completely eluted and the
concentration of DNA is not verified concurrently, calculations of incorporation percent-
age can vary widely; second, though not originating within the DNA double helix, Auger
electrons and low energy photons coming from the ISI of iodine in the nucleus can still
contribute to dose enhancement of the cells. Iodine that adheres not to the nuclear DNA,
but rather to cell membranes or at other sites in the cell, acts as a contrast agent adding
dose, but does not exhibit high-LET killing behavior(Corde et al., 2004). The range of
these densely ionizing particles is much shorter than the dimensions of the cell, and so an
Auger cascade resulting from an ISI of iodine elsewhere in the cell is unlikely to affect the
DNA.
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Table 4.1: Iodine measurements in various cell compartments.
per cell Iodine Atoms (×108) Percentage of Total Dose to Nucleus
per Iodine ISI
(mGy)
Whole Cell 6.8 100 -
Cytoplasm† 2.0 30 0.349
Nucleus 4.8 70 3.01
Nuclear DNA 3.4 50 3.01
† Measurement includes membranes and other particulates as described in Section 4.3 and
so S-value is average of cytoplasm and cell surface values.
Substitution percentages reported here are significantly lower that others have observed
(Miller et al., 1995, 1992) for the same cell line and similar exposure times and concen-
trations. Differences reflect variability in cell culturing technique, DNA isolation, and the
method of measuring iodine (e.g. NAA and HPLC). We believe our protocol to be free of
major flaws and that ICP-MS is the most robust technique in iodine measurement given
current technology. Also, after the first few detailed studies on incorporation , most investi-
gators have cited the incorporation results of the original sources rather than independently
measuring incorporation(Corde et al., 2004; Shinohara et al., 1996); it has been upward of
15 years since the original sources. Interpretation of cell survival will follow and should
vindicate our measurements (See Chapters VII and VIII).
54
CHAPTER V
IRRADIATION PROCEDURES
5.1 125I Seeds
Low energy radiation below the K-edge of iodine was carried out using 125I seeds (On-
coseed Model 6711, Oncura Inc., Plymouth Meeting, PA). Seed activity was verified in
a calibrated, well ion chamber upon delivery and after irradiation to confirm exponential
decay; dose rates between measurements were interpolated accordingly. The seed stock,
which included 5 seeds of 8.49 mCi and 8 seeds of 5.64 mCi assayed upon arrival, was ar-
ranged in a 14 mm COMS eye plaque seed carrier (Trachsel Dental Studio Inc., Rochester,
MN) as shown in Figure 5.1 to ensure uniform dosimetry at 0.5 cm treating distance.
Dosimetry plans were carried out with Plaque Simulator 5.3.6 (BEBIG, Eckert & Zeigler,
Berlin, Germany) and accounted for source decay, seed carrier attenuation, anisotropy, and
irradiation geometry.
Radiation was administered by attaching the seed carrier to a plastic jig that was made
to ensure 0.5 cm treating distance. Each well of the plating dish has 15.5 mm diameter
and with 0.75 mL of medium the surface level is 39 mm from the cell monolayer. These
dimensions are important to keep uniformity in dose as well as to ensure sterility with no
contact between the seeds and the medium. Irradiation times were pre-calculated using
the software, but dose was validated in situ by TLDs (see Section 5.5) Irradiation took
place in a shielded, locked incubator to ensure proper incubation environment during longer
exposures.
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Patient: _________________________, Right eye, !T = 169.50 hrs
Plaque Simulator l  i l  Loading Diagram
Plaque Simulator™ 5.3.6 Monday, November 16, 2009 12:42 PM (licensed to Demonstration mode) Page 1  of 1 
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UNLICENSED
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Isotope summary:
Plaque# 1 2 3 4
Isotope
Inventory name
Number of sources used
Assay date
Avg. source strength @ assay
Total strength @ assay
Total strength @ implant
Isotope
Inventory name
Number of sources used
Assay date
Avg. source strength @ assay
Total strength @ assay
Total strength @ implant
I-125 (6711 TG43U1)
medium
8
8/7/09
5.45 mCi
43.60 mCi
31.76 mCi
I-125 (6711 TG43U1)
high
5
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8.20 mCi
41.00 mCi
29.87 mCi
FRONT: COMS 14
(concave view)
3.97mCi
3.97mCi
3.97mCi
3.97mCi
3.97mCi
3.97mCi
5.97mCi
5.97mCi
5.97mCi
5.97mCi3.97mCi 3.97mCi5.97mCi
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5.97mCi
5.97mCi
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5.97mCi 3.97mCi3.97mCi 5.97mCi
Figure 5.1: Arrangement of 125I Seeds: ensures uniform dose at 0.5 cm treatment distance
to within 5%.
5.2 Radioactive Holmium
Radioactive holmium was produced in the VUMC cyclotron as described in Chapter II.
The helium-cooled target holder was implemented to achieve higher beam current (20 mA)
and longer irradiation time (2.5 hours) without compromising the foil. Upon extraction
from the cyclotron, the foil was shielded and brought to said incubator where it was attached
to the same jig and fixed at 0.5 cm treating distance within one of the wells. Treatment times
were estimated by ion chamber exposure rate readings upon creation, but again dose was
verified by TLDs.
5.3 300 kVp X-rays
Orthovoltage x-rays were created from a PANTAKTherapax DXT 300 (Elimpex-Medizintechnik,
Moedling, Austria) held at 300 kVp and 10 mA in a square, collimated 10 cm x 10 cm field
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at a treatment distance of 50 cm SSD where the dose rate was calibrated to 2.2 Gy/min.
The filter set consisted of 1.5 mm of aluminum and the half-value-layer was measured to
be 0.75 mm of copper.
5.4 137Cs Irradiator
A 2562 Curie, 137Cs source controlled pneumatically in a Mark I irradiator (JL Shep-
pard & Associates, Glendale, CA) with rotating turntable was used to ensure uniform dose
during irradiation. The mean treatment distance was approximately 25 cm resulting in a
dose rate of 1.8 Gy/min. Internal shielding limited the radiation to the 662 keV 137mBa
gamma-rays.
5.5 Dosimetry
Thermoluminescent Dosimetry
Thermoluminescent dosimeters (TLDs) were used in each irradiation to verify dose.
As radiation interacts with crystalline structures (LiF in our case) it causes electrons in the
crystal’s atoms to jump to higher energy states, where they stay trapped due to impurities
(magnesium and titanium, in the case of TLD-100) in the crystal, until heated. Heating
the crystal causes vibrational modes (phonons) which in turn release the trapped electrons,
and they drop back to their ground state, emitting a photon of energy equal to the energy
difference between the trap state and the ground state. Thermoluminescent (TL) response,
measured in µC of charge, is calculated from the integral of the glow curve in the TLD-
reader (Harshaw Model 3500 with WinREMS software package, Saint-Gobain Crystals &
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Detectors, Solon, OH). Basically, the reader heats the TLD at a constant rate (see NOTE)
and its photomultiplier tube measures the amount of light emitted at each step on the heating
slope. The number of photons emitted is proportional to the number of electrons released
which is ultimately proportional to the amount of dose deposited by the original radiation.
Differences in LET of radiation source will lead to different patterns of dose distribution in
the LiF crystals, thus necessitating an independent calibration of each radiation source (see
Section 5.5).
NOTE: Recommended time-temperature profile (TTP) for 1/8”x1/8”x.035” TLD-100
chips according to user manual is as follows: preheat temperature of 50◦C for 0 seconds;
acquisition rate of 10◦C/sec to a maximum temperature of 300◦C for 33 1/3 seconds; the
anneal condition is 300◦C for 0 seconds, which means that the TLDs are annealed at the
end of each reading automatically.
Placement
For the 125I seeds and radioactive holmium, only one well of cells was irradiated at a
time, and because of the proximity of the radiation source, it was important to measure the
uniformity as well as the magnitude of the dose distribution to the entire well. To accom-
plish this, a plastic jig was made to house nine TLDs flush against the bottom of the plate.
The TLDs were arranged in a 3 x 3 matrix that spanned the entire area of the irradiated
well. The mean dose to the cells was calculated as the average readings of the nine TLDs.
Experiments in which any individual reading was greater than 2-sigma from the mean (95%
confidence interval) were discarded. For the x-ray tube and cesium irradiations, four wells
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Figure 5.2: TLD housing jigs for in vitro irradiation. Left: jig for iodine and holmium
irradiations. Cutout is just big enough to fit the 3x3 TLD configuration as well as to have
full coverage of one of the wells in the culture dish. Middle: jig for cesium and x-ray tube
irradiations. Cutouts are big enough to fit individual TLDs and are centered on each well
in the dish. In both jigs, the cutouts are deep enough to ensure that TLDs are flush against
bottom surface of dish. Right: 24-well culture dish used in all experiments.
of drug containing cells and four wells of control cells were irradiated simultaneously. To
verify dose uniformity, a separate plastic jig was made to house one TLD centered on each
irradiated well, flush against the bottom of the plate. Since the treatment distance for these
sources is much larger, the dose uniformity within each well was not in question, especially
since the dose was found to be uniform among all wells in the same plate.
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Calibration
TLDs are known to have energy-dependent sensitivity(Cheunga et al., 2007; Pradhan
and Quast, 2000; Meigooni et al., 1988; Jung et al., 2003). To account for this, a calibra-
tion experiment was performed for each source. Small variations exist between individual
TLDs, and so each TLD was labeled and close attention was paid to ensure proper book-
keeping of each. In order to account for this variability, an element correction coefficient
(ECC) was measured for each. The entire batch of TLDs (~20) were exposed to a known
dose of each radiation source:
For 125I and 137Cs, TLDs were irradiated by point sources of each at set distances to
achieve a calculable dose. (A series of experiments were done that exposed TLDs to these
point sources at various distances, and therefore various dose rates, to create a sensitivity
curve for the dose rate dependence, but no significant dependence was observed.) To mimic
the energy and dose rate of radioactive holmium, the TLDs were irradiated by the Louisiana
State University Center for Advanced Microstructures and Devices (LSU-CAMD) syn-
chrotron at 35 keV and 0.13 Gy/min and the dose normalized to their calibration, which
averaged beam-line ion chamber readings and film dosimetry values1. Orthovoltage x-ray
tube dose was validated by ion chamber upon recent commission of the machine.
After each radiation source exposure, the entire batch was measured and their individual
responses were recorded, normalized to the mean response. If an individual TLD response
was more than 1-standard deviation from the group’s mean response for any of the radiation
sources, that TLD was discarded entirely, not to be included in any of the experiments. The
ECC for each TLD was this ratio of its response to the mean. With this information, the TL
1Performed by Joseph P. Dugas. Relevant citations are (Dugas et al., 2008; Oves et al., 2008).
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response can be corrected by simply multiplying the ECC by the reading (charge, q). Once
each ECC has been calculated and recorded, the experiment is repeated; the symbols and
error bars in Figure 5.3 illustrate the results for each radiation source. Since the TLDs were
exposed to a known dose of radiation, and we know the variation in each individual TLD,
we can calculate the conversion between the charge reading and the dose of radiation: the
reader calibration factor (RCF) is the average slope of each source curve. Once the RCF
is recorded for each radiation source we have a complete calibration, and so if TLD i is
exposed to an unknown dose of radiation from radiation source j, the dose, D, can be
calculated as D= q×ECCiRCFj .
The energy dependence of TL response should closely mimic the trend of absorption
in the material. The inset of Figure 5.3 shows the ratio of the mass-energy attenuation
coefficient of LiF to water in the relevant energy range, normalized to unity at 662 keV
for the gamma ray from 137Cs decay. Since LiF’s absorption is higher for lower energy
photons, relative to water, an over-response of TL sensitivity is expected for lower energy
sources. The plotted lines on the main axes are projections of the 137Cs data that have been
corrected by the relative response ratio at the appropriate energy of each radiation source.
Notice the data points follow the trend well and so the methodology of TL dosimetry is
justified.
5.6 Radiation Survival
Cells were plated at a density of 3×104 cells/cm2 in each well and incubated overnight
to attach to the plate and begin in exponential growth. On the second day, half the wells
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Figure 5.3: TLD energy-dependence. Symbols and error bars are the mean ± 1 standard
deviation of 8 independent measurements of each radiation source at each dose. Plotted
lines are theoretical projections, normalized to the 137Cs response, based on the ratio of
mass-energy attenuation coefficients of LiF to water taken from NIST (inset).
were aspirated of their growth medium and exposed to 20 µM IUdR (most efficient con-
centration for incorporation, see Section 4.3) diluted in growth medium. The other half
served as the control wells, and were simply refreshed with growth medium. Cells were
then left to incubate for two days (again, for highest incorporation). On the fourth day, both
sets, now at 75-85% confluency, were aspirated, refreshed with growth medium, and im-
mediately taken to be irradiated. Drug-containing medium was aspirated for two reasons:
to ensure that the only IUdR available for the cells during repair was that which had bound
to the DNA originally; and to limit the effects of iodine as a contrast agent, which has been
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shown to cause a low-LET type background sensitization(Corde et al., 2004). For x-ray
tube and cesium irradiations, one set of each (one control and one drug) was not irradi-
ated, but still transported with the rest to exactly mimic the conditions; these were used for
plating efficiency calculations. For iodine and holmium irradiations, for whichever cell set
was being irradiated, a corresponding non-irradiated set was brought to the same incubator
and shielded for similar plating efficiency calculations to take into account any difference
in incubation environment. After irradiation, all cells were brought back to the original
incubator, and left to incubate overnight to allow repair to begin. On the fifth day, each
well was washed with PBS, trypsinized, centrifuged, and resuspended in 5 mL of growth
medium. Cells were then plated in TC-treated, 100 mm diameter Petri dishes (Corning #
430167) at low densities (4000-10000 cells per dish) and left to incubate for 10-14 days.
Three dishes were plated for each well to get sufficient statistics. Cells were then fixed
with 3.7% paraformaldehyde for 5 minutes, rinsed, stained with 0.05% crystal violet, let sit
for 30 minutes, then rinsed twice with tap water and drained inverted for several minutes.
Colonies of 50 cells or more were counted. Colonies of less than 50 comprised of cells
that have survived fewer than 5 replications and so have been sufficiently mutated to be
considered non-survivors.
Statistical Analysis
Plating efficiencies were calculated for each irradiation and data were normalized to
100% survival at zero dose. Each data point consisted of the mean and variance of the
three colony counts. These data were then fitted to a linear-quadratic exponential model for
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surviving percentage S, S = e−αd−βd2 by a weighted, non-linear least squares algorithm.
The number colonies counted was, by design, high enough to keep the counting (Poisson)
uncertainties on the order of a few percent. The variance was dominated by the ~10%
uncertainty in hemacytometry and cell culturing, and so a constant variance of 10% was
used; weights in the fit were then variance−1at each point. Reduced chi-square values
around unity validate this choice of weights.
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CHAPTER VI
SURVIVAL COMPARISON
Radiation survival curves for irradiation of HT-29 cells by each of the radiation sources
are plotted in Figure 6.1 on the same axes. Note that all of the control curves are rela-
tively well clustered together. The LETs of our radiation sources range from 1− 10 keVµm
(Makrigiorgos and Waker, 1986; Hunter and Muirhead, 2009). The relative biological ef-
fectiveness (RBE) of radiation at these values of LET are close to unity(Barendsen, 1968)
and so no spread in radiation survival was expected in the controls. Data points from two
other investigators (Sekhar et al. (2007) irradiated HT-29 cells with 300 kVp x-rays; Miller
et al. (1987) used 250 kVp x-rays) are included to validate slope and shape of the control
curves, as well as to illustrate variability between laboratories.
Sensitization, defined by any means, was smallest for 125I irradiation between drug-
and control-curves. This absence of an effect is dominated by the fact that almost the entire
spectrum of 125I falls belows the K-edge of iodine, above which the peak in absorption
occurs and an inner-shell ionization is possible. Relative to water, iodine absorbs better
at all x-ray energies, but above the K-edge, the ratio of absorption is greatest. Since this
radiation-drug combination takes advantage of neither a difference in relative absorption,
nor the added dose from an atomic re-stabilization cascade, this result comes without sur-
prise.
Cesium irradiation brings about the second lowest sensitization among the radiation
sources. Contrary to 125I, radiation from 137Cs decay falls entirely above the K-edge of
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Figure 6.1: Survival curves for HT-29 cells irradiated by each radiation source, with and
without 2-day exposure to 20µM IUdR.
iodine. The reason for a diminished sensitization is that at 662 keV, iodine’s absorption is
nearly identical to that of water and so the DER is near unity. Also, at this energy, almost
all of the energy deposited in an iodine atom results from inelastic (Compton) scattering
and so the probability of an inner-shell photoelectric ionization is minuscule. Again, given
the hypothesis that IUdR is most effective just above the K-edge of iodine, this result is not
unexpected.
Orthovoltage x-rays more efficiently activated IUdR because of their proximity to the
K-edge of iodine. Still, because of the polychromatic nature of the x-ray tube output, the
full extent of sensitization is partially masked. In fact, 9.9% of the spectrum lies below 33
keV or above 200 keV; these photons contribute 20.2% of the total dose. Below the K-edge
of iodine, photons are unable to cause an ISI and therefore can not trigger the added dose
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from electron re-stabilization. Above 200 keV the photoelectric cross-section for iodine
falls dramatically, decreasing the probability of an ISI. This suppression of the full efficacy
of photon activation therapy is the main reason for the diminished results in vitro, as well
as in the clinic.
Radioactive holmium, whose spectrum is pictured in Figure 4.1, is our solution to this
dilemma. From the survival curve in Figure 6.1, we illustrate how by selection of a photon
source with the majority of the spectrum above the K-edge of iodine (but not too far as to
diminish photoelectric ionization), optimal sensitization can be achieved. Using the same
criteria as for the x-ray tube, 81.5% of the spectrum contributing 70.1% of the total dose
fall between the 33 and 200 keV; the majority of these detrimental photons are 25.4 keV
and can be filtered by design to further optimize the spectrum. Note: Copper encapsulation
would be useful to conceal this low energy peak, much like titanium encapsulation of 125I
seeds is used to suppress beta emission.
The task remains to quantify the enhancement for each radiation source, including a
thorough inspection of each dose enhancement mechanism. Table 6.1 summarizes the ra-
diation source characteristics, dose calculations, and survival fits for each. To visualize
the cumulative progression effect of each dose enhancement mechanism, we have plotted
(1) the original no-drug survival curve (control), (2) the curve with only the nuclear DER
added, (3) the curve with the nuclear DER plus the contribution of added dose from ISI
re-stabilization, and (4) the drug curve in Figure 6.2. True sensitization beyond mere dose
enhancement is isolated between curve (3) and (4). Again since SERs require arbitrary
choice of the independent variable, we use the more robust measure of dose-response, ∆α ,
to understand the governing mechanism of sensitization. We note a trend in the difference
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of α that is not merely dependent on mean energy of the radiation source; ∆α increases
as the activation energy steps past the K-edge of iodine, but then decreases beyond this
energy. Recall that we hypothesized that an increasing number of ionized iodine atoms
should result in more high-LET radiation, and so IUdR is most effective when activated
just above the K-edge of iodine. Plotted in Figure 6.3 is the difference in α in the drug
curve (4) and the theoretically dose enhanced curve (3), ∆α , in units of Gy−1 , versus the
number of ionizations per Gray for each source. The trend is nearly linear with minimal
offset and a slope of 0.293.
Thus far, we have not been able to quantify the decrease in β and relate it to a physical
mechanism. β seems to stay nearly constant between drug and control curves, and so it
could represent the inherent radioresistance of the cell line, probably owing to the efficiency
of the line’s DNA repair system. Also, since αβ is dramatically increased in the drug curve
relative to the control, and the point at which dose = αβ is well beyond the data, this may
be an artifact of the fitting procedure. In all fits except for the 125I control (no-drug),
however, the uncertainty in α is much less than the value of β , so the fits can be trusted,
statistically. The α− (high-LET) dominance of the drug-containing survival curves is the
central thesis of this study; it carries the most information about sensitization, leads to the
most effective tumor cell killing, and in doing so, overshadows the minimal curvature effect
(β -dependence).
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6.1 Dose Rate Considerations
Survival effects have a known dependence on dose rate of the irradiating source. In our
experiments, the initial dose rate delivered to the cell cultures ranged from 0.86 Gy/min for
the 125I seeds up to 1.68 Gy/min for the 137Cs source. Also, with the 2.48 hour half-life
of the radioactive holmium, the dose rate is exponentially decaying during irradiation. It is
worth mentioning that there are established ways to account for the relative effectiveness of
a given radiation prescription based on dose rate as well as the number of fractions in which
the full dose is delivered. Quantities like Biologically Effective/Equivalent Dose (BED)
and Relative Effectiveness (RE) have been established to, for the former, provide a way
to predict the different biological effect between fractionation regimens for external beam
therapy. The latter quantity provides a multiplicative correction to the dose prescription
based on continuous irradiation by an exponentially decaying source. It has the form:
RE∞ = 1+
R0
µ+λ
￿
β
α
￿
where R0 is the initial dose rate, µ is the exponential repair constant for the relevant
cell line, λ is the exponential decay constant of the radiation source, and α and β are the
linear-quadratic fit parameters of the survival curve (the subscript ∞ denotes that the source
is left to completely decay) (Dale, 1985). We do not speculate how this treatment would
apply to our survival comparison, but rather include it for thoroughness. A diligent in vivo
trial would certainly need to take this effect into account.
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CHAPTER VII
QUANTIFYING HIGH-LET EVENTS
We need to extract some physical meaning from this trend. We have claimed that α is
a measure of the number of high-LET events and that from a difference in α between the
drug-curve and the dose enhanced curve (∆α) we could isolate the mechanism of enhance-
ment. But in order to support the validity of our trend, we must first identify a candidate
event that leads to cell killing in such a way that mimics high-LET behavior; one such
event is a double stranded break (dSB) in nuclear DNA. Studies on the cell killing mech-
anisms of radioactive 125IUdR, for example, have linked the high-LET beta radiation to
an increase of the number of dSBs relative to lower-LET external radiation(Kassis et al.,
1987; Sundell-Bergman and Johanson, 1980; Karnas et al., 2001). The number of dSBs is
not necessarily directly proportional to cell death, but it is a useful estimate of biological
effectiveness (McMillan et al., 2001). But at what rate are dSBs created in cells with iodine
incorporated in the nuclear DNA? Humm and Charlton (1988) calculated for iodine that
0.663 double strand DNA breaks occur per ionization cascade. Recall the interpretation of
the units of our trend: we found that ∆α (the most fundamental way to measure the number
of high-LET events) was proportional to the number of ionizations of iodine bound to the
nuclear DNA, and that the constant of proportionality was 0.293 ionizations−1. This means
that 29.3% of the ionizations lead to high-LET effects. Provided our calculations and those
of Humm are correct, we now have an estimate of how effective dSBs are to cell killing. If
0.663 dSBs occur per ionization, and we find a contribution to ∆α of 0.293 per ionization,
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then on average, it takes ~2 dSB per nucleus to form enough non-repairable lesions to nu-
clear DNA to cause cell death (either by apoptosis or chromosomal aberrations) after two
weeks of proliferation. This value fits well to the conclusions of most studies on the lethal-
ity of non-repairable dSBs. For radiosensitive cell lines, more dSBs are found per lethal
death because of the inherent inability of the cell to correctly repair dSB damage (Dahm-
Daphi et al., 1994; Iliakis et al., 1992). For radioresistant lines, however, the number of
dSBs per lethal event approaches unity(Kysela et al., 1993; Blocher and Pohlit, 1982).
This result validates the methodology of isolating the mechanisms of cell killing en-
hancement: addition of dose and quality of radiation. The only thing that remains is a
treatment of β . Our data show that β decreases significantly in the drug curve from the
theoretically dose enhanced curves, as expected, since several repairable lesions in one cell
caused by the low-LET external radiation source could be completely concealed by only
one non-repairable cell-killing lesion in the same cell. In fact, this decrease in β , along
with the substantial increase of α/β , is the essential validation to this theory; an increase
of α alone would isolate the dose enhancement as the primary sensitization mechanism.
Instead, from the dependence of ∆α on the number of iodine ionizations, we see that the
ionizing cascades created from these ISIs constitute the dominant mechanism.
NOTE: In our calculation of added dose to the nucleus from ISIs of iodine, we included
only self absorption for a single cell and have ignored the addition of dose from adjacent
cells. The data in Goddu et al. (1996) indicates a decrease of a factor of 2 in the dose
absorbed in the nucleus originating in the cytoplasm relative to that which originates on the
cell membrane for cells of our size. This factor of 2 gives an estimate of the distance scale
of the dose distribution. We know that the range of the Auger electrons and other densely
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ionizing particles is much less than the dimensions of the cell, and so it is reasonable to
assume that ISIs of iodine atoms outside the nucleus (never mind the adjacent cells) will
not contribute to dSB production. Their dose might, however, increase the total DER to
the nucleus of an adjacent cell. This inclusion would slightly decrease the slope of Figure
6.3, and therefore decrease the contribution of dSBs to cell killing; the necessity of ~3-4
dSBs to cause cell death may be more plausible. Also not included in this calculation are
“bystander” effects. Single particle microbeam experiments have shown that a significant
number of cells that are neighbored by irradiated cells, but not themselves directly traversed
by the ionizing particle, undergo chromosomal aberrations and cell death.
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CHAPTER VIII
ANALYZING PAST LITERATURE
Since we have come up with a way to translate the underlying radiobiology to survival
effects, we can use apply this formalism to previously reported results. Data from Miller
et al. (1987) is plotted in Figure 8.1. Regrettably, the authors did not provide explicit char-
acteristic data of the x-ray tube used other than the 250 kVp potential and 1.65 Gy/min dose
rate. For consistency, we assumed similar filtering and current as our tube, and simulated
the spectrum using two independent software programs: SpekCalcOSX (Poludniowski and
Evans, 2007; Poludniowski, 2007) and SPEKTR (Siewerdsen et al., 2004). The simulated
beam’s characteristics were in good agreement using both packages and are listed in Table
8.1. Simulated dose rate was slightly lower than reported, but without knowledge of the
driving current or filtration used (or the method of measurement), we could not alter this
dose rate without significantly changing the shape of the output spectrum.
Since only percentage substitutions were reported, and not absolute iodine content,
we also needed to simulate the iodine distribution in the cell. Again for consistency we
used our measured cell size, compartmental distribution, and thymidine density and simply
scaled the number of iodine atoms by the percentage replacement reported. Given the
simulated x-ray spectrum and iodine distribution, we performed identical dose deposition
analysis and survival curve projections; the results are tabulated in Table 8.1.
The implications of the higher substitution percentage are best illustrated in Figures 8.2
and 8.3. The main consequence of more iodine incorporation is higher absorption, which
75
Ta
bl
e
8.
1:
Su
rv
iv
al
da
ta
fr
om
M
ill
er
et
al
.(
19
87
).
D
os
e
de
po
si
tio
n
an
d
su
rv
iv
al
pr
oj
ec
tio
ns
ca
lc
ul
at
ed
us
in
g
sa
m
e
an
al
ys
is
th
at
pr
od
uc
ed
Ta
bl
e
6.
1
↓P
ar
am
et
er
/I
nc
or
po
ra
tio
n
%
→
16
(0
.5
µM
)
21
(1
µM
)
25
(2
µM
)
31
(5
µM
)
D
ER
to
nu
cl
eu
s
1.
84
2.
10
2.
31
2.
63
K
−i
on
iz
at
io
ns
nu
cl
eu
s·G
y
5.
35
7.
02
8.
36
10
.4
C
as
ca
de
D
os
e
(%
)
1.
71
2.
25
2.
67
3.
32
N
o
D
ru
g
(α
|β
|α
/β
)
0.
1
.0
45
2.
22
0.
1
.0
45
2.
22
0.
1
.0
45
2.
22
0.
1
.0
45
2.
22
A
fte
rD
ER
(α
|β
|α
/β
)
.1
84
.1
52
1.
21
.2
10
.1
99
1.
06
.2
31
.2
40
.9
62
.2
63
.3
10
.8
46
A
fte
rC
as
ca
de
do
se
(α
|β
|α
/β
)
.1
87
.1
58
1.
19
.2
15
.2
08
1.
03
.2
37
.2
53
.9
37
.2
71
.3
31
.8
19
D
ru
g
(α
|β
|α
/β
)
0.
5
.0
35
14
.3
.6
.0
25
15
.0
.7
50
.0
25
30
.0
.9
5
.0
25
17
.5
Be
am
ch
ar
ac
te
ri
st
ic
s:
Fl
ue
nc
e:
2.
16
×1
01
2
γ
G
y·c
m
2
;D
os
e
R
at
e:
1.
34
G
y
m
in
;T
ub
e
Po
te
nt
ia
l:
25
0
kV
p;
M
ea
n
Ph
ot
on
En
er
gy
:7
4.
6
ke
V
;M
ed
ia
n
Ph
ot
on
En
er
gy
:5
9
ke
V
;H
V
L:
7.
59
m
m
A
l,
0.
45
2
m
m
C
u.
76
0 2 4 6 8 1010
−6
10−5
10−4
10−3
10−2
10−1
100
Dose (Gy)
Su
rv
ivi
ng
 F
ra
cti
on
 
 
Control (0% Substitution)
16% Substitution (0.5 µM IUdR)
21% Substitution (1 µM IUdR)
25% Substitution (2 µM IUdR)
31% Substitution (5 µM IUdR)
37% Substitution (10 µM IUdR)
Figure 8.1: Survival Curves with several % IUdR-thymidine substitutions fromMiller et al.
(1987).
is quantified as the DER. Although a 250 kVp x-ray spectrum is not ideal, we see that these
factors of 2-4 increase in the number of iodine atoms leads to huge DERs, which would
then lead to increasingly steeper survival curve; one such projection is pictured in Figure
8.2. The dotted line is the measured control for irradiations of HT-29 cells in the absence
of any drug, to various doses of the 250 kVp x-ray tube. The dot-dashed and dashed lines
are the projections of the survival curve given the addition of dose stemming from the
DER, and the DER plus cascade dose, respectively. Recall that these projections represent
simple calculations of the fundamental physical process of absorption and as such, dictate
the minimum sensitization effect on cell survival; they do not account for an increase of
ionizing density of the Auger cascade or the introduction of a foreign object into the DNA
macromolecule. The actual measurement of the drug curve, however, tells the true story.
The solid line plots the survival curve of cells exposed for 2 days to 5µM IUdR leading to
a measurement of 31% thymidine replacement. Notice that the measured drug curve is not
nearly as steep as the calculations project it should be.
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Figure 8.2: Measured vs. projected survival curve given calculated DER and Cascade Dose
for 31% substitution from Miller et al. (1987).
This plot presents several interesting paradoxes. Even though the progression of α and
β follow the similar pattern from control through projections to drug curves, we see for
the first time that the projections are much steeper that the measured drug curves. We also
see for the first time that β dominates both projections; this on its own is not contradictory
since such an increase in absorption due to this high of an iodine incorporation would lead
to much more low-LET radiation being absorbed in drug containing cells. We saw similar
(albeit much less pronounced) increases in β with our projections, but this artifact was
overwhelmed in the drug curve by a substantial increase in α that led to steeper survival
curves and more efficient cell killing. Here though, the increase in α is not sufficient to
dominate, which bring about another, perhaps more interesting observation illustrated in
Figure 8.3.
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Figure 8.3: Calculated contribution of K-ionizations to α for all incorporation percentages.
When comparing the fully dose-enhanced curve to the drug curve in our analysis, we
found a trend in the difference in the linear component, ∆α , that was proportional to the
number of ISIs. This trend was logical since we hypothesized that the Auger cascade
stemming from an ISI was a main source of the potency of ionization and subsequent cell
killing. Also in support of this hypothesis was the proportionality constant whose unit
analysis led to agreement with conclusions in relevant literature about the ballpark number
of dSBs required to kill a cell. After similar analysis of the data from Miller et al. (1987),
a similar trend is found. The result is a highly linear correlation, but whose proportionality
constant is 0.04, more than 7 times less than the one we measured. The implications of
their measurements are that it takes on average ~16 dSBs per cell to kill it, which is higher
than even the strictest skeptics would estimate.
This contradiction could have one of two solutions. Our methodology could be severely
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flawed, and we stumbled on the accepted value accidentally, or their incorporation measure-
ment has overestimated the situation. Their method for measuring iodine content included
elution of nucleosides by way of high pressure liquid chromatography (HPLC) and agreed
well with even older studies that used neutron activation analysis (NAA: (Nath et al., 1987;
Laster et al., 1993)). Given the near extinction of NAA facilities and the ubiquity of mass-
spectrometry in chemical labs around the country, we stand by the claim that our mea-
surements of absolute iodine content, and the compartmental distribution thereof, are the
most accurate to date. Furthermore, our analysis of dose enhancement and sensitization is
based on first-principle physics and nearly free of assumptions. We only assumed that the
linear-quadratic model is the most appropriate and that each component carries physical
information about the relation between the cause of cell death and the LET of the radiation
that induced it. These assumptions are independently attested and have endured decades of
scrutiny and remain the most popular. The only other data borrowed was from the world-
renowned studies of Humm and Charlton (1988), innovators in Monte Carlo simulations of
biodosimetry whose methods and conclusions remain as the basis of current models. With
this in mind, we confidently claim to be fairly assessing the fundamental physical phenom-
ena of radiation-induced cell death, and have uncovered a highly efficient method thereof
to fight cancer.
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CHAPTER IX
CONCLUSIONS
It should be clear that 161Ho can be feasibly and inexpensively produced at sufficient
activity to be useful therapeutically. Furthermore, having such a short half-life, our source
would be ideal for fractionation treatment (normal prescriptions are 2 Gy per day). Com-
mercial production of sealed seed sources (much like procedures already in place for other
radioactive seeds) would lead to versatile clinical applications including matrix arrange-
ment of seeds to cover larger treatment areas and complex, pre-planned dose distributions.
We have shown that the x-rays emitted from radioactive holmium are highly appropriate for
the activation of IUdR. We have isolated mechanisms of dose enhancement from each other
as well as from the mechanisms of radiosensitivity, and in doing so, have extracted infor-
mation about fundamental physical processes of DNA breakage. Through this independent
formalism and a phenomenological assay of cell survival, we have made conclusions about
the lethality of DNA dSBs that agree with the literature. Furthermore, we have developed
an objective protocol to analyze sensitization effects that obviates an arbitrary choice of
measurement criteria. Sensitization values from holmium irradiation reported here are by
far the greatest given the uptake of our drug, even on a notably radioresistant cell line. Most
importantly, since holmium is a feasible material for brachytherapy implants, the full effi-
cacy of this combination therapy, which has gone unexploited for 60 years, can finally be
realized. Our results suggest that in vivo studies and clinical trials of IUdR photo-activation
with holmium brachytherapy merit consideration.
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APPENDIX A
DER CALCULATION CODE (HOLMIUM)
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